Maintenance of Marketing Authorizations of Medicinal Products in the MENA Region – Differences and Similarities to European Procedures

Wissenschaftliche Prüfungsarbeit
zur Erlangung des Titels „Master of Drug Regulatory Affairs“
der Mathematisch-Naturwissenschaftlichen Fakultät
der Rheinischen Friedrich-Wilhelms-Universität Bonn
vorgelegt von
Zohaira El Malahi

aus Wissen
Bonn 2018
Danksagung


Auch bei meinen Geschwistern, meinem Mann und dem Rest meiner Familie möchte ich mich bedanken, dass sie sowohl in guten als auch in schwierigen Lebenslagen für mich da waren und mich bei meinen Vorhaben immer unterstützt haben.

Außerdem gilt mein Dank all meinen Bekannten, die ich in dieser Zeit kennengelernt habe. Das Team des DGRA sowie allen Dozenten verdanke ich eine schöne Studienzeit und viele lehrreiche Vorlesungen.
Table of Content

Danksagung ........................................................................................................................... iii
List of Figures ........................................................................................................................ vii
List of Tables ........................................................................................................................ viii
List of Annexes ................................................................................................................... ix
List of Abbreviation ........................................................................................................... x

Executive summary ............................................................................................................. 1

1. Introduction in Regulatory Affairs Department in MENA .............................................. 2
   1.1. Definition of MENA and geographical location ....................................................... 2
   1.2. Pharmaceutical & Healthcare sector in the MENA region ........................................ 4
   1.3. Overview of Competent Authorities in the MENA region ........................................ 7
      1.3.1. Competent Authorities in the Gulf States ............................................................ 7
      1.3.2. Competent Authorities in the Levant countries .................................................. 9
      1.3.3. Competent Authorities in the Maghreb States ................................................... 12
      1.3.4. Gulf Central Committee for Drug Registration .................................................. 13

2. Marketing Authorization in the MENA Region .............................................................. 14

3. Maintenance of Approved Medicinal Products – Middle East and North Africa ................. 18
   3.1. Renewal as procedure to maintain marketing authorizations in the MENA Region ... 18
   3.2. Renewal procedure in the countries of the MENA region .................................... 21
      3.2.1. Renewal application in the Gulf States ................................................................. 21
         3.2.1.1. Kingdom of Saudi Arabia ............................................................................. 21
         3.2.1.2. United Arab Emirates ............................................................................... 23
         3.2.1.3. Bahrain ....................................................................................................... 24
         3.2.1.4. Oman ......................................................................................................... 26
         3.2.1.5. Qatar .......................................................................................................... 27
         3.2.1.6. Kuwait ........................................................................................................ 27
      3.2.2. Renewal application in the Levant States .......................................................... 28
         3.2.2.1. Egypt ........................................................................................................ 28
         3.2.2.2. Iraq ............................................................................................................. 30
         3.2.2.3. Kurdistan ................................................................................................... 31
         3.2.2.4. Iran ............................................................................................................. 31
3.2.2.5. Israel ......................................................................................................................... 33
3.2.2.6. Jordan ...................................................................................................................... 35
3.2.2.7. Lebanon .................................................................................................................. 37
3.2.2.8. West Bank .............................................................................................................. 38
3.2.3. Maghreb States ........................................................................................................ 39
3.2.3.1. Morocco .................................................................................................................. 39
3.2.3.2. Algeria .................................................................................................................... 40
3.2.3.3. Tunisia .................................................................................................................... 42
3.2. Other procedure to maintain a marketing authorization of a medicinal product in the MENA region ................................................................................................. 44
3.2.1. Gulf States ............................................................................................................... 45
3.2.2. Levant States ............................................................................................................ 46
3.2.3. Maghreb States ........................................................................................................ 47
3.3. Harmonization of renewal procedure in MENA region ............................................. 48
4. Differences and Similarities to European Procedures ................................................. 50
4.1 Renewal procedure for medicinal products authorized via CP, DCP and MRP in the European Union ................................................................................................. 50
4.1.1 Centralized procedure............................................................................................... 50
4.1.2 Decentralized procedure/Mutual recognition procedure .......................................... 52
4.1.4 Other maintenance procedures in the European Union .......................................... 53
4.2. Differences and Similarities between the procedures in the MENA Region and the European Union ................................................................................................. 54
5. Summary, Discussion and Outlook ........................................................................... 59

List of References ........................................................................................................... 61
Annex I - Application Form for Renewal application in KSA ........................................ 68
Annex II - Application Form for Renewal of a conventional medicinal products UAE 82
Annex III - Renewal Application Form for General sale - UAE .................................... 95
Annex IV - Application form for Renewal for Herbal Medicinal Product - UAE .......... 104
Annex V - Renewal Application Form – Bahrain ............................................................ 113
Annex VI - Renewal Checklist – Bahrain ....................................................................... 114
Annex VII - Application Form for Marketing and Renewal Application - Oman ........ 115
Annex VIII - Renewal Checklist – Kuwait ....................................................................... 119
Annex IX - Renewal Application Form – Egypt .............................................................. 121
Annex X - Renewal Checklist – Iraq
Annex XI – Application Form for renewal of chemical entities - Israel
Annex X - Renewal Checklist for Biologicals – Israel
Annex XIII - Renewal Checklist – Application form for Marketing and Renewal Application - Jordan
Annex XIV – Application Form for Renewal - Palestine
Annex XV – DMP Application Form for Renewal - Morocco
Annex XVI – LCNM Application Form for Renewal - Morocco
Annex XVII – Application Form for Renewal - Algeria
Annex XVIII – Annex A Application Form for Renewal - Algeria
Annex XIX – Annex II Application Form for Renewal - Algeria
Annex XX – Required documents for renewal of CP products
Annex XXI – Required documents for renewal of DCP or MRP products
List of Figures

Figure 1: Overview of countries of the MENA region................................................................. 2
Figure 2: Increase of Diabetes as widespread disease in the world ........................................... 4
Figure 3: Development of MENA Health Expenditure in comparison with other markets........ 5
Figure 4: Number of pharmaceutical companies in the countries of the MENA region (private and non-private companies) ...................................................................................... 6
Figure 5: Definition of CTD dossier according to ICH.............................................................. 16
Figure 6: Schematic figure showing the renewal process of a marketing authorization........... 22
List of Tables

Table 1: Overview about Sunset Clause in the Gulf States ......................................................... 45
Table 2: Overview about Sunset Clause in the Levant States ..................................................... 46
Table 3: Overview about Sunset Clause in the Maghreb States ................................................. 47
Table 4: Differences and Similarities between EU and MENA .................................................. 58
List of Annexes

Annex I - Application Form for Renewal application in KSA .................................................. 68
Annex II - Application Form for Renewal of a conventional medicinal products UAE ............. 82
Annex III - Renewal Application Form for General sale - UAE ................................................ 95
Annex IV - Application form for Renewal for Herbal Medicinal Product - UAE ................... 104
Annex V - Renewal Application Form – Bahrain ....................................................................... 113
Annex VI - Renewal Checklist – Bahrain ................................................................................. 114
Annex VII - Application Form for Marketing and Renewal Application - Oman ...................... 115
Annex VIII - Renewal Checklist – Kuwait .................................................................................. 119
Annex IX - Renewal Application Form – Egypt .......................................................................... 121
Annex X - Renewal Checklist – Iraq ......................................................................................... 124
Annex XI – Application Form for renewal of chemical entities - Israel .................................. 126
Annex X - Renewal Checklist for Biologicals – Israel ............................................................... 128
Annex XIII - Renewal Checklist – Application form for Marketing and Renewal Application - Jordan ................................................................................................................................................. 132
Annex XIV – Application Form for Renewal - Palestine ............................................................. 139
Annex XV – DMP Application Form for Renewal - Morocco ...................................................... 140
Annex XVI – LCNM Application Form for Renewal - Morocco ................................................ 141
Annex XVII – Application Form for Renewal - Algeria .............................................................. 144
Annex XVIII – Annex A Application Form for Renewal - Algeria ............................................. 147
Annex XIX – Annex II Application Form for Renewal - Algeria ................................................. 148
Annex XX – Required documents for renewal of CP products ................................................. 149
Annex XXI – Required documents for renewal of DCP or MRP products ................................. 154
# List of Abbreviation

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANPP</td>
<td>National Agency of Pharmaceutical Product</td>
</tr>
<tr>
<td>ANSM</td>
<td>Agence nationale de sécurité du médicament et des produits de santé</td>
</tr>
<tr>
<td>API</td>
<td>Active Pharmaceutical Ingredient</td>
</tr>
<tr>
<td>CA</td>
<td>Competent Authority</td>
</tr>
<tr>
<td>CAPA</td>
<td>Central Administration of Pharmaceutical Affairs</td>
</tr>
<tr>
<td>CEP</td>
<td>Certificate of Suitability of Monographs of the European Pharmacopoeia</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee of Human Medicinal Product</td>
</tr>
<tr>
<td>CMS</td>
<td>Concerned Member State</td>
</tr>
<tr>
<td>CP</td>
<td>Centralised Procedure</td>
</tr>
<tr>
<td>CTD</td>
<td>Common Technical Document</td>
</tr>
<tr>
<td>DCP</td>
<td>De-Centralised Procedure</td>
</tr>
<tr>
<td>DGPA &amp; DC</td>
<td>Directorate General of Pharmaceutical Affairs &amp; Drug Control</td>
</tr>
<tr>
<td>DHA -</td>
<td>Dubai Health Authority</td>
</tr>
<tr>
<td>DMF</td>
<td>Drug Master File</td>
</tr>
<tr>
<td>DMP</td>
<td>Direction des Médicaments et de la Pharmacie</td>
</tr>
<tr>
<td>DTA</td>
<td>Iraqi Directorate of Technical Affairs</td>
</tr>
<tr>
<td>DPM -</td>
<td>Pharmacy and Medicine Directorate</td>
</tr>
<tr>
<td>eCTD</td>
<td>electronical Common Technical Document</td>
</tr>
<tr>
<td>EDA</td>
<td>Egyptian Drug Authority</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EPAR</td>
<td>European Public Assessment Report</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FOB</td>
<td>Free On Board</td>
</tr>
<tr>
<td>GCC – DR</td>
<td>Gulf Central Committee for Drug Registration</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practices</td>
</tr>
<tr>
<td>HA</td>
<td>Health Authority</td>
</tr>
<tr>
<td>HAAD</td>
<td>Health Authority of Abu Dhabi</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference of Harmonization</td>
</tr>
<tr>
<td>KDFC -</td>
<td>Kuwait Drug and Food Control Administration</td>
</tr>
<tr>
<td>KMCA -</td>
<td>Kurdistan Medical Control Agency</td>
</tr>
<tr>
<td>JFDA -</td>
<td>Jordan Food and Drug Administration</td>
</tr>
<tr>
<td>LNCM</td>
<td>Laboratoire National de Contrôle des Médicaments</td>
</tr>
<tr>
<td>MENA</td>
<td>Middle East North Africa</td>
</tr>
<tr>
<td>MoH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MOHME</td>
<td>Ministry of Health and Medical Education</td>
</tr>
<tr>
<td>MoPH</td>
<td>Ministry of Public Health</td>
</tr>
<tr>
<td>MRP</td>
<td>Mutual Recognition Procedure</td>
</tr>
<tr>
<td>MSDS</td>
<td>Material Safety Data Sheet</td>
</tr>
<tr>
<td>NHRA</td>
<td>National Health Regulatory Authority of Bahrain</td>
</tr>
<tr>
<td>NODCAR -</td>
<td>National Organization for Drug Control &amp; Research</td>
</tr>
<tr>
<td>NORCB -</td>
<td>National Organization for Research and Control of Biologics</td>
</tr>
<tr>
<td>PIL</td>
<td>Product Information Leaflet</td>
</tr>
<tr>
<td>PSUR</td>
<td>Periodic Safety Update Reports</td>
</tr>
<tr>
<td>QP</td>
<td>Qualified Person</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>RMS</td>
<td>Reference Member State</td>
</tr>
<tr>
<td>SFDA</td>
<td>Saudi Food and Drug Authority</td>
</tr>
<tr>
<td>SmPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>TSE</td>
<td>Transmissible Spongiform Encephalopathy</td>
</tr>
<tr>
<td>USA</td>
<td>United States of America</td>
</tr>
</tbody>
</table>
Executive summary

The aim of this master thesis is to identify and define the regulatory requirements for maintenance procedures of marketing authorization for medicinal Products in the countries of the Middle East and North Africa.

The importance of marketing authorizations of medicinal products is not only limited in the approval of new marketing authorization. It is more important to maintain existing marketing authorizations in these countries to ensure the prevention, diagnosis and treatment of diseases and for patient rehabilitation.

In the last 10 years the MENA region has become one of the most emerging markets in the world. This is due to the growth of the population, the increasing affluence and the increase of life expectancy. Inside the region, the tendency of the increased numbers of MAH and manufactures increased since several is still ongoing and the authorities are developing and modifying new regulations and laws in order to justify this development.

Even the developing process of adequate regulations for medicinal products is still ongoing, in most of the MENA countries there are a lots of challenges. Many of the regulations are only available in Arabic. For the Maghreb States the submission dossier has to be provided in French. Additionally the political situation in some MENA country is not stabile and the processes are not transparent enough. These barriers complicate the authorization and maintenance for medicinal products in the MENA region. Finally the population has to face up with the consequence of these barriers.

This master thesis will provide an overview about the maintenance procedures for marketing authorizations in the MENA region and to compare them with the European procedure. This comparison conveys how far the development of the pharmaceutical sector in the MENA region is in opposite to Europe and how the trend will develop in the next years.
1. Introduction in Regulatory Affairs Department in MENA

The MENA region is one of the “emerging” markets in the pharmaceutical sector in the world. The importance of this region for many multinational pharmaceutical companies is very high. This section will provide some basic information to gain a better understanding of how the pharmaceutical market is organized and to maintain a marketing authorization in the MENA region.

1.1. Definition of MENA and geographical location

The term “MENA” is defined as “Middle East and North Africa” and includes in general 22 countries from Morocco at the eastern border until Iran in the north of the region. (1)

Due to the fact, that a firm definition does not exist, there are several opinions that Turkey belongs to the MENA region. In this case we will follow the definition of the World Bank and exclude Turkey in this analysis.

According to the Word Bank and UNICEF the following countries belongs to the MENA region: Algeria, Bahrain, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates (UAE), West bank and Yemen. (2)
Inside the MENA region we have to divide three subgroups:

**Middle East:**
- GCC countries: Saudi-Arabia, UAE, Bahrain, Oman, Qatar, Kuwait, Yemen
- Levant countries: Iran, Iraq, Syria, Lebanon, West Bank, Jordan, Israel, Egypt, Libya: These countries are not part of any union. (3)

**North-Africa:**
- Maghreb-States: The countries Morocco, Algeria and Tunisia belong to the Maghreb countries.

The political situation in the MENA region is middling. Since the beginning of the Arab revolutions in 2011, the political situation in some countries is quite instable. In Syria, Yemen and Libya the current situation is not transparent and there are still civil wars in these countries. The medical supply is quite inadequate and the procedures to authorize import or maintain medicinal products into the affected markets are not up-to-date and not in use. Due to this fact these three countries will not be taken into account for the aim of this master thesis.
1.2. Pharmaceutical & Healthcare sector in the MENA region

The pharmaceutical and healthcare sector in the MENA region grows up since the 1970’s. The need of medicinal products and healthcare was growing up due to the growth of the population of 532 Million people. The increased life expectancy of the population and the decreased death mortality are one of the most important reasons. Additionally, the change of the life cycle during the last years leads to many widespread diseases, such as Diabetes, cancer or cardio-vascular diseases. (4)

The region belongs to one of the Emerging markets in the world after China. The amount of the MENA region in the world belongs to $32 Billion dollar, which makes only a percentage of 2 percent. (5) The pharmaceutical sector is estimated to grow from 9 to 11 percent until 2020. (6)

Figure 2: Increase of Diabetes as widespread disease in the world

Source: https://www.huffingtonpost.com/riva-greenberg/diabetes-stats_b_4273505.html

The increased demand of medicinal products is shown in the figure. The amount of people with diabetes will be increased in the MENA region about 96.2 percent until 2035.

Inside the MENA region nearly all competent authorities and Institutions are in the process to develop easier procedures for granting authorization of medicinal products to counteract against this need. This challenge leads to the growth of the pharmaceutical sector in the region. Since 1970 more than 140 local pharmaceutical companies are located in countries of the MENA region.
Most of the domestic pharmaceutical companies are generic drug manufacturer. This is due to the fact that the development of new innovative drug substances is not well advanced in the MENA region. A large part of the countries are dependent on import of medicinal products from USA, Europe and China. Especially for the manufacturing, the import of active drug substances and ingredients are essential. This heavy dependence aggravated the development of the pharmaceutical sector in the MENA region.

Another point is the strong individuality and the status of development inside the MENA region. The Gulf States are well-advanced in the development of appropriate procedures and regulations, but the Maghreb States are backward in this case. In the Maghreb States a strong dependence on laws, regulations and procedures during and after the authorization of medicinal products to the French Authority ANPP. This can be judged from the fact that the price for medicinal products in Algeria, Morocco and Tunisia are similar to the actual prices of medicinal products in France.

In the last decade, local authorities and institutions are in the progress of developing appropriate procedures for authorization and maintenance of MA of medicinal products in regard to ICH-Guidelines. This development leads also to an increase of the amount of privatization of pharmaceutical companies.
The figure shows, that the pharmaceutical market size in almost all countries is mainly generated by state-own enterprises, except for Iraq, where private pharmaceuticals companies makes more than 50 percent of the market size. It is expected that the amount of private companies will increase in the next years. This development shows that with the privatization of companies in the countries leads to more independence on imports of medicinal products in the region.

All these points show that the development of the pharmaceutical industry in the MENA region is in progress, but many important milestones still need to be reached. In contrast to the industrial nation as the United States, Europe or Japan the development and manufacturing of new innovative drug substances and biologicals are not well developed in the countries of the MENA region. Additionally the manufacturing and authorization of medicinal products is difficult in many countries, due to the long approval timelines of the authorities. The missing resources inside the authorities complicate the access of pharmaceutical products to the local markets. In nearly all countries the Ministries of Health contain appropriate departments for authorization of medicinal products instead of European countries, where “own” competent authorities are responsible for marketing authorization and post-approval activities of medicinal products.
1.3. Overview of Competent Authorities in the MENA region

To understand the procedure of the maintenance of marketing authorizations in the MENA region it is important to get an overview about the National Competent Authorities in each country.

1.3.1. Competent Authorities in the Gulf States

Kingdom of Saudi Arabia (KSA)

Since 2003 the Saudi Food and Drug Authority (SFDA) is the competent authority for registrations, maintenance, quality, pharmacovigilance and import of medicinal products. (7) It is an independent authority from the Ministry of Health.

United Arab Emirate (UAE)

Seven Emirates belongs to the United Arab Emirate. Abu Dhabi (the capital), Dubai, Sharjah, Ajman, Umm Al-Qaiwain, Ras Al-Khaimah and Fujairah.

In UAE there are two competent authorities who are responsible for all regulatory issues of medicinal products.

The Health Authority of Abu Dhabi (HAAD) is responsible for medicinal products in the capital emirate Abu Dhabi and for Dubai it is the Dubai Health Authority (DHA). For the other emirates, the Ministry of Health and Prevention is responsible for all drug related issues. For the management and regulation of health services the Health Authority of Abu Dhabi and the Dubai Health Authority merged together. (8)

Bahrain

For all pharmaceutical issues as licensing, healthcare professional's regulation, Healthcare facilities regulation and complaints the National Health Regulatory Authority of Bahrain (NHRA) takes the responsible. (9) The NHRA is an independent institution to the Ministry of Health.
Oman

The Directorate of Pharmaceutical Affairs & Drug Control as part of the Ministry of Health is responsible for registration, import, maintenance and quality of medicinal products authorized in Oman. (10)

Qatar

In Qatar, the department of Pharmacy & Drug Control as part of the Ministry of Public Health takes the responsibility for all drug related issues such as registration, quality control, inspection and drug release. (11)

Kuwait

The Kuwait Drug and Food Control Administration (KDFC) is part of the Ministry of Health. This department is the competent body for all drug related issues as quality control, authorization and assessment of marketing authorizations for medicinal products. (12)
1.3.2. Competent Authorities in the Levant countries

**Egypt**

The Egyptian Drug Authority (EDA) is a competent authority body within the MoH, which is responsible for issues regarding authorization and control of medicinal products. (13)

- The Central Administration of Pharmaceutical Affairs (CAPA) is an entity within the EDA, which takes the responsibility for the assessment and licensing for medicinal products. (14)
- The National Organization for Drug Control & Research (NODCAR) is responsible for all Quality related issues of nationally authorized products in Egypt. (15)
- For Biologicals the National Organization for Research and Control of Biologics (NORCB) is the main department of authorization, import & quality related issues for Biologicals. (16)

**Iraq**

In Iraq there is a special situation. The Iraqi Directorate of Technical Affairs (DTA) as part of the MoH is responsible for all drug related issue as registration, inspection and quality control for medicinal products in the Iraqi market. (17)

Since 1992 the MoH in the Kurdish autonomous area establish the Kurdistan Medical Control Agency (KMCA). This competent body is responsible for the registration, quality control, distribution and quality control of medicinal products in Kurdistan. (18)

**Iran**

The Food and Drug Department of the Ministry of Health and Medical Education (MOHME) is responsible for all issues related to the authorization, maintenance and marketing of medicinal products in Iran. (19); (20)

**Israel**

For the authorization, control and marketing of medicinal products (human, herbal and veterinary products) the MoH in Israel is responsible. The Registration Department is responsible for the licensing processes while the Institute for
Standardization and Control of Pharmaceuticals is responsible for the quality control of authorized medicinal products in Israel. (21); (22)

Jordan

The Jordan Food and Drug Administration (JFDA) belong to the MoH and take the responsibility for licensing processes for medicinal products and food products.

Inside the JFDA the Registration Division is the main directorate for the authorization for medicinal products in Jordan. (23)

Lebanon

The Ministry of Public Health (MoPH) is responsible for all drug related issues.

The “Service of Pharmacy” as part of the MoPH has the following activities:

- Issuing certificates related to pharmacies and pharmacists’ practice
- Drug pricing
- Drug industry management and control
- Narcotic drugs’ imports, distribution, and statistics
- Medicinal imports(exports
- Drug registration and control
- Registration of non-medicinal health-related items
- Pharmacies’ and drugstores’ inspection
- Controlling fraud in the pharmaceutical industry (24)

West Bank

The General Directorate of Pharmacy as part of the Ministry of Health take the responsibility of all licensing, quality control and price issues for medicinal products authorized and marketed in Palestine. Inside the Directorate there are separate departments for each section

- Registration Department
- Drug Quality Department
- Pharmaceutical Policy Department
- Dangerous Drug Department (narcotics and psychotropic drugs)
- Drug Information Department
• Import and Export Department (25)

For the authorization of medicinal products, medical devices, food products and cosmetic products the Drug Registration Department of the General Directorate of Pharmacy is the main contact point. (26)
1.3.3. Competent Authorities in the Maghreb States

**Morocco**

In Morocco, the Ministry of Health is the main body for healthcare for public health. The department "Direction des Médicaments et de la Pharmacie" (DMP) is responsible for all drug related issue, as authorizations, maintenance, monitoring and distribution of pharmaceutical products. (27)

**Algeria**

The “Pharmacy and Medicine Directorate” (DPM) is an independent body of the Ministry of Health and Population, which is responsible for all regulatory topics for medicinal products. (28) Since 2017, the National Agency of Pharmaceutical Product (ANPP) replaced the DPM and took the responsibility as independent and non-government agency for all drug related issues as drug registration, maintenance and distribution. (29) (30) (31)

**Tunisia**

The Ministry of Public Health is the main body related to regulatory issues for medicinal products. Since 1981 the Directorate of Pharmacy and Medicine (DPM) is a part of the Ministry of Public Health is responsible for the management of drug related issues in Tunisia. (32)
1.3.4. Gulf Central Committee for Drug Registration

The Gulf Central Committee for Drug Registration is a committee founded by six of the Gulf States in 1999. The members of the committee are

- Saudi Arabia
- Qatar
- Oman
- Bahrain
- Kuwait
- United Arab Emirates
- Yemen

The committee is responsible for the assessment and authorization of medicinal products, which should be authorized via the “Central Drug registration”. Marketing authorizations from the GCC-DR will get a marketing license for all members of the GCC. (33)
2. Marketing Authorization in the MENA Region

In the last years, the MENA region became more important for international pharmaceutical companies. This is due to the fact that 32 Billion Dollar was made in pharma sales and the trend is still growing (34).

Inside the MENA region, besides the diversity of culture, language, and tradition, there are significant differences in the processes for obtaining marketing authorizations in the countries. Therefore, it is difficult to describe the processes for the whole region. In this part we will take the opportunity to summarize the most important parts of marketing authorizations in the MENA region.

A main reason for the complexity and diversity of the processes for marketing authorization of medicinal products are due to the development of the health- and pharmaceutical sector in the respective countries. In the last years significant progresses were done in the MENA region, mainly in the GCC-States and in some Levant States as Egypt and Israel. The numbers of local manufacturers increased in this region over the recent years. (34). This indicates that the region tries to get independent from medicinal products imported from other parts of the world. The pharmaceutical and health sector grows in these countries also due to the increased population and medical needs in this region.

Even there are positive trends for the whole region, inside the MENA region there are significant differences in the regulatory “know-how” and experience. While many GCC countries and several Levant States as indicate much progresses in the healthcare and pharmaceutical development and regulatory of medicinal products, the Maghreb States are not on the same level. There is a historical background behind the significant differences inside the MENA region. Until 1956 the Maghreb States were under French colonial power and this had a major impact on all administrative bodies, including the Ministries of Health and the Committee for all drug related issues. Especially the Algerian and Tunisian Authorities often refer to the decision of the French NCA ANSM (Agence nationale de sécurité du médicament et des produits de santé).
Maintenance of Marketing Authorizations in the MENA Region

Despite the numerous progresses in the recent/past few years, there are still many aspects inside the pharmaceutical sector, which are not yet regulated adequate enough. The NCA of the MENA region have limited experience in the fields of biologicals and gene-therapy. Their experience with such kind of medicinal products cannot be compared with the European or American NCA’s. There are only a few special laws and regulations for these kinds of medicinal products and this indicates that this field is still in progress. (35)

The timeline to get a marketing authorization depends on certain countries. A general statement is not possible. While the authorization procedures in the GCC States, Maghreb States and some Levant countries take 2 – 4 years, the same procedure can take up to 5 years in Iraq and Iran, even it is the same dossier for a medicinal product, which were submitted to other MENA countries. In comparison to this, a marketing authorization for a Centralized procedure in Europe takes 300 days, including the decision of the European Commission.

In the most countries of the MENA region, a local agent is required for the communication and the submission to the Health Authorities. For a MAH outside the respective country, it is not allowed to submit any application to the authorities, except for medicinal products, which were authorized centrally by the Drug Registration of the GCC (GCC-DR). Due to this fact, many multi-national companies have several establishments in these countries to facilitate the communication to the authorities and to fulfill the local requirements. The local agent is the main contact point between the local authority and the MAH. This obligatory is a problem for small and medium enterprises, because due to financial aspects and the short range not every company can establish local agents in these countries. The result is that medicinal products of these companies cannot be marketed in the MENA region or only a small portfolio is available.

Another important role beside the local contact point in the certain country is the format of the dossier. Nearly all countries require the dossier as CTD format (agreed in line with the ICH-M8 Guideline), but till now it is not possible to submit the dossier electronically in all countries of the MENA. Especially in some Levant states and in the Maghreb states, an electronically submission of an eCTD is currently not possible. (36)
Many authorities still require the dossier in hard and soft copies as CDs/DVDs. The reason for this is that many countries are not yet ready for eCTD submissions because the technical conditions are still missing. On the contrary, Saudi Arabia and Bahrain require eCTD submissions via electronically portals since 2015. (37) In Egypt and Lebanon, the CTD is still not implemented. The documents have to be provided electronically as simple pdf dossier via Email and paper-based. (38)

For the Maghreb States, the documents in the CTD should be provided in French. This leads to a serious problem for the applicant, because for the two biggest markets - the US and Europe and most of the countries in the world, the language requirements of submission dossiers are in English. Therefore, it is quite complicated if the whole submission package needs to be translated into French. This additional workload leads to a high workload and a massive loss of time for the applicant.

Another special feature for marketing authorizations is that all authorities required a legalized CPP from the country of origin (COO). This requirement is valid for all MAH outside the respective country. The country of origin is defined as the country where the batch release takes place. (39)

It is also required, that the medicinal product has a valid license in the COO. In many countries it is not possible to maintain a marketing authorization (MA) without a valid license in the country of origin. If the MA is expired in the COO, the HA’s requires a justification in the application form.
All these points have to be taken into account for pre- and post-marketing authorization activities especially for renewal procedures.

The assessment processes at the authorities’ sites are not transparent and clear to the applicant. The timelines are not well communicated and this leads to the consequence that the applicant has to consider a delay for market access of the medicinal product due to the absence of information about the timelines and the assessment process. Due to the missing information about timelines, the applicant must always be prepared for further requests from the authorities at any time of the renewal procedure.

Another point of discussion for receiving a marketing authorization in the MENA region is the fact, that there are no mutual recognition procedures inside the region. The authorities do not accept any approvals from other authorities of the region for guarantying a MA in the respective country. In opposite to the countries of the European Union, where a MA can be guaranteed via the Centralized, De-centralized or Mutual Recognition procedures, only national procedure for MA is available. The only exception is the central authorization procedure in the Gulf States. Since 1999 it becomes possible to get a marketing license for a medicinal product with one central procedure for all Gulf States and Yemen. Therefore, the Applicant has to submit a dossier for marketing authorization to the Gulf Central Committee for Drug Registration (GCC-DR) and after the assessment and the positive approval, the medicinal product can be marketed in all Gulf countries.
3. Maintenance of Approved Medicinal Products – Middle East and North Africa

This part contains information about relevant procedures to maintain a marketing authorization of a medicinal product in the MENA Region. The main focus is the description of “renewal procedures” in this region. The first part of this section will be an overview about the renewal processes in the MENA region as whole region and in each individual country. In the second part of this section, there will be a discussion about other procedures to maintain a marketing authorization in different countries. The last part of this section will expand the issue of availability of harmonization processes of renewal or other “maintenance” procedures in the MENA region.

3.1. Renewal as procedure to maintain marketing authorizations in the MENA Region

For all countries in the Middle East and North Africa the Marketing Authorization holder is obligated to submit a renewal application to maintain the marketing authorization in the relevant countries.

As mentioned in the previous part, the MAH should have a local agent within a country, if the MAH is stated outside the affected country. This local agent is responsible for the renewal application and he is stated as main contact point for the authorities.

Due to the fact that the development of regulations affecting the marketing authorization of biological are still in development, the requirements for renewal applications do not differ between chemical entities and biological. Only in Israel and Egypt, the national competent authorities require other documents for the renewal applications for chemical entities and for biologicals. (40); (41)

In general, all marketing authorizations have to be renewed every 5 years from the beginning of the initial registration. Except in Iran the timelines for renewal of marketing authorization is 4 years. (42) In Israel there is the exemption that if the product is not changed in the manufacturing processes; the renewal has to be done 10 years after the initial registration.
The renewal application has to be submitted within the last year of the marketing authorization. Most of the countries require that the applicant has to submit the dossier within 3 upon 9 months before the marketing authorization expires. In Jordan, it is usually that the renewal will be submitted at latest 6 months after expiry of the marketing authorization. (43) (44)

In many MENA countries it is required to submit the dossier of the initial marketing authorization to the competent authorities for renewal application. It is unusual to submit a shortened dossier containing only Module 1 and Module 2 for the initial renewal application. For further renewals, some authorities as the DMP in Morocco only require a cover letter containing a declaration that the license should be continued in the relevant country. (45)

In some countries, there are minor differences between the required documents from local manufactured where the MAH is stated in the country and for imported products, where the MAH is stated outside the country. In cases that the medicinal products where imported from foreign countries, the authorities always require a CPP of the country where the batch release takes place. For renewal applications, the applicant has to submit a list of all approved variations, which were submitted and approved during the time of the marketing authorization. This requirement is valid for all MENA countries.

In many MENA countries, a valid license of the current manufacturing site is a condition for submission of renewal applications. Especially in the Gulf and Levant states, the authorities require a “manufacturing site renewal” before the renewal of the marketing authorization. Without a valid manufacturing license, a renewal application for a MA is not possible.

Another important requirement for a renewal application in the MENA region is a valid marketing authorization in the country, where the MAH is stated (except the MAH is stated in one country of the MENA region). Some countries refer during the renewal assessment to the marketing authorization and the opinion of FDA, EMA or from other authorities. For the Maghreb States as Algeria, the opinion of the French authority ANPP will be take into consider for the assessment. (46)
Nearly all countries require a submission of a renewal application dossier as CTD sequence. In the Gulf countries, a submission of an eCTD becomes mandatory. (36), (39) (47)

In other countries, a submission of hard and soft copies of the dossier to the NCA’s is required. Only in Egypt and in Lebanon a submission of the renewal as CTD format is not possible. It is required to submit the dossier via Email or as hard copy to the different departments of the authorities, which are involved in the assessment of the renewal application. (48); (49); (50)

The timeline for renewal applications in the MENA countries are different. The assessment timelines can take from 15 days up to 24 months. In Tunisia the assessment of a renewal takes only 15 days, but in Egypt a renewal application can take up to 24 months. (51) In general, a renewal application takes 6 months. For a part of the countries, a procedure timeline is not applicable.

Another important point to consider is the fact, that in most cases the assessment procedure after submission of the renewal application is not well communicated to the applicant. Due to this fact, the applicant has to consider that the authorities may send questions or a request for more documents to any time of procedures. Additionally the approval of the renewal application cannot be foreseen and this should be involved in the planning of the submission.

The countries of the MENA region are very individual and every authority refers to their own standards. In the next section, the renewal application for each country will be discussed.
3.2. Renewal procedure in the countries of the MENA region

In this section, the renewal procedure in each country will be discussed. At the beginning, the procedure of renewal in the GCC States, the Levant States and the Maghreb States will be specified.

3.2.1. Renewal application in the Gulf States

3.2.1.1. Kingdom of Saudi Arabia

Legal Basis

In the “Law of Pharmaceutical Establishments and Preparations” from 2004 and the “Executive Rules of the Institutions and Pharmaceutical Products Law” the mandatory for renewal of a MA in KSA is stated. The renewal application has to be submitted within 6 months before the marketing authorization expires. (37) (47)

Required documents

The Applicant has to submit the renewal dossier in CTD format. The application form for renewals is the same as for the initial marketing application. (37) (47)

For the renewal application it is mandatory to submit the Module 1 and Module 3 within the CTD format to the SFDA. It is mandatory to submit the renewal dossier electronically via “Saudi Drug Registration System (SDR System). Additionally, it is required to submit the dossier via paper.

The following documents are required for the submission (52)

Module 1

- Cover Letter
- Application form [Annex I - Application Form for Renewal application in KSA]
- Table of content
- Product Information
- Certificate of suitability for TSE, and the
- price list
Maintenance of Marketing Authorizations in the MENA Region

For MAHs, which were not stated in Saudi Arabia it is required to include a Certificate of Pharmaceutical Product (CPP). \( \text{(52)} \)

- The CPP from COO

Module 3

- specification of the drug substance \( \text{(3.2.S.4)} \)
- specification of the finished product \( \text{(3.2.P.5.1)} \)
- stability data of the finished drug product \( \text{(3.2.P.8).} \)

Assessment procedure and timelines

The renewal process can be divided into two main phases.

---

**Figure 6: Schematic figure showing the renewal process of a marketing authorization**

Source - Saudi Food & Drug Administration Regulatory Framework for Drug Approvals (version 5.0)

The validation phase (Phase II) takes 10 days for authority to ensure that all requirements for the renewal application were fulfilled by the applicant.

The next phase is divided into three main sub-processes:

- The related product manager will start the assessment by distributing the renewal application to three departments (Quality, Efficacy, and Safety). All
three departments have to finish the assessment within 50 days and forward their assessment reports back to the project manager. (47)

- Within 30 days the price department has to check the rules for pricing of the affected medicinal product. (47)

- Lastly, the inspection department of the Authority checks if the manufacturing line is valid to the last inspection. If there are any changes, which were not included in the last valid inspection report, the manufacturing site has to be inspected again. This phase can take up to 50 days.

After this processes the assessment report of the renewal application will be forwarded to the “Renewal committee”. Within 10 days the committee can decide about the renewal application for approval, rejection or ask for further information from the applicant.

After the positive approval of the renewal application, the marketing authorization is valid for 5 years. (47)

3.2.1.2. United Arab Emirates

Legal Basis

For medicinal products authorized in the Arab Emirates, the Circular 28 and 29 from 2007 describes the mandatory and requirements for renewal applications of medicinal products. (53)

A marketing authorization for a medicinal product in UAE is valid for 5 years. To maintain a marketing authorization for medicinal products in the UAE it is required from the Ministry of Health to submit a renewal application within 3 months before the marketing authorization expires. (53)

Required documents

The Ministry of Health differs between originator and generic medicinal products. Additionally it is required to use different application forms for the renewal of “commercial medicinal products”, herbal medicinal products, and products for general sales. (54)
The MAH or the local partner (if the MAH is stated outside the UAE) is obligated to submit a renewal application. It is required to submit the following documents: (54)

- Cover Letter
- Application form
  - [Annex II - Application Form for Renewal of a conventional medicinal products UAE];
  - [Annex III - Renewal Application Form for General sale - UAE];
  - [Annex IV - Application form for Renewal for Herbal Medicinal Product - UAE]
- declaration for the intention of the renewal of a marketing authorization. This declaration is important; otherwise the Authority will withdraw the marketing license for the affected medicinal product without notification. (54) for MAH located outside of UAE
- legalized CPP from COO
- approved SmPC, PIL and approved artworks

The applicant has to submit an appointment for the submission of the renewal and have to pay the fees before submitting.

Assessment procedure and timelines

After submission of the required documents, the Registration Department will send a confirmation about the receipt of the renewal dossier to the Applicant. The renewal procedure will take 3 months after submission of the dossier. (54)

3.2.1.3. Bahrain

Legal Basis

The Pharmacy Law 18 from 1997 clearly states, that a medicinal products authorized in Bahrain needs a valid license for manufacturing and sales purposes. In Bahrain, a renewal application should be submitted every five years. (39)

Required documents

The NHRA has published a Renewal Guideline which includes all relevant information for the applicant.
For the renewal application, it is required that the manufacturing site registration is still valid at the time of the renewal. Any variation should be approved before the renewal application, while a common submission of a renewal and a variation application for the same medicinal product is not allowed. (39)

The renewal application should be submitted via eCTD. The dossier should include the following documents: (39)

- Cover letter
- application form for renewals in Bahrain (see Annex V - Renewal Application Form – Bahrain)
- checklist from the NHRA for renewal applications [Annex VI - Renewal Checklist – Bahrain]
- approved SmPC, PIL and artworks
- CPP of the country where the batch release of the medicinal product takes place.
- A valid GMP certificate of the manufacturing site
- Certificate of Suitability for TSE
- Certificate of analysis for the active substance and the finished drug product and
- Manufacturing registration certificate in Bahrain.

Assessment procedure and timelines

The application should be submitted three months before the marketing authorization expires. Before the submission, the Applicant has to request an appointment of submitting the renewal application.

For the renewal application, it is mandatory to perform a laboratory analyze of the medicinal products upon assessment. Therefore, the NHRA requires samples of the product and several certificates of the product composition, method of analysis, product specification and safety data of the material used in the medicinal product. (39)

There is no timeline for the renewal assessment for medicinal products in Bahrain.
3.2.1.4. Oman

Legal Basis

A special feature for marketing authorizations in Oman is that the process of “renewal” is called “re-registration” at the Ministry of Health (MoH) and the Directorate General of Pharmaceutical Affairs & Drug Control (DGPA&DC).

As in all Gulf countries, the renewal of a marketing authorization has to be done every 5 years. The renewal application should be submitted within 6 months before the expiry date of the marketing authorization of the affected medicinal products. (55)

Required documents

Before submission of the “re-registration” the applicant has to submit a “submit request” to the MoH before submitting the renewal application.

The applicant has to submit the renewal application via eCTD. The following documents have to be provided (55)

- Cover Letter
- Application form (see Annex VII - Application Form for Marketing and Renewal Application - Oman]
- Samples of the medicinal product
- Pharmacovigilance system
- Risk Management Plan
- CPP
- Certificate of analysis for drug substance & finished product
- Alcohol content declaration
- Pork content declaration
- diluents & color agents in the product formula
- Price list

Assessment procedure and timelines

The DGPA & DC does not publish any information about the timelines and the procedures for re-registration of marketing authorizations in Oman.
3.2.1.5. Qatar

In the “Law No. 1 of 1986 on the Registration of Pharmaceutical Companies and their Products” it is not stated, that a renewal application for medicinal products authorized in Qatar is required. (56).

Moreover the MoH in Qatar does not publish any information about information about renewal procedures for national marketing authorizations. It can therefore be concluded that a renewal application for a MA of a medicinal product is not required in Qatar and a MA receive an unlimited validity after approval.

Only if the product was approved via the centralized GCC procedure, a renewal according the GCC is required. The renewal application of the centralized procedure in the GCC region will be discussed in a later section.

3.2.1.6. Kuwait

Legal basis

In the ministerial decree 302/80, it is stated, that a medicinal product has to be renewed. The decree is not available for the public. The MoH publish a guidance document for the submission of registration and renewal applications based on the ministerial decree. (57)

A renewal application has to be submitted within 3 months before the MA expires.

Required documents

The following documents are required for the renewal application: (57)

- checklist for renewal application [Annex VIII - Renewal Checklist – Kuwait]
- legalized CPP
- currently approved SmPC
- long term and accelerated stability studies from production batches
- Samples of the finished medicinal product

Assessment procedure and timelines

Information about the assessment procedure and the timelines are not available.
3.2.2. Renewal application in the Levant States

In this section, the renewal process of marketing authorization of medicinal products in Levant states will be discussed.

3.2.2.1. Egypt

Legal Basis

The renewal of medicinal products in Egypt is regulated in two main ministry decrees. For medicinal products, the decree 425/2015 includes all requirements for registration in Egypt. (48) For Biologicals, the renewal process is described in the Ministry decree 297/2009. (58)

For medicinal products according to Ministry Decree 425/2015 the renewal process should be done every 10 years. (48) For Biologicals, a renewal of the marketing authorization is required every 5 years. (58)

There is no exact timeline, when the Marketing Authorization Holder has to submit the renewal application to the authority. In the Ministry Decree, it is only stated that the submission should be done in the last year of the expiry date of the marketing authorization. (48), (58)

Required documents

For local and imported medicinal products, the renewal should be performed within 2 years after the previous registration certificate. (48), (58)

In Egypt, the submission dossier cannot be submitted as eCTD sequence. The applicant has to submit the dossier as simple PDF documents.

The renewal application should be submitted to the following email addresses:

- For human drugs: hf296@eda.mohealth.gov.eg
- For Biologicals: Biological_App@Eda.mohealth.gov.eg (59)

It is mandatory to send a request before submission to the EDA. For medicinal products, it is required to submit the following documents: (48), (58)

- request form the latest certificate of registration, and the latest price certificate.
Maintenance of Marketing Authorizations in the MENA Region

- for biologicals, the applicant should provide beside the certificate of analysis and the latest price certificate, a list of all variations, the last batch release certificate and the renewal fee receipt.

After reply of the authority on the request for the renewal, the applicant has to submit a “preliminary re-registration file” via Email. This dossier should contain: (48); (58); (59)

- Application form [Annex IX - Renewal Application Form – Egypt]
- Registration certificate
- legalized CPP
- Letter of Authorization between MAH and local partner
- registration fees receipt

Procedure and Timeline

The EDA will inform the applicant via “Renewal Status Letter” that the marketing authorization is under renewal registration.

At the same time, the applicant has to submit the “preliminary re-registration file” to the following department for approval:

- Scientific committee: If no scientific reference is available
- Egyptian Pharmacovigilance Center
- Technical committee communication section:
- Naming & labels committee: if the trade name was changed or for the approval of changes of the labeling for post-stability and pharmacology committee
- Variation committee
- Pricing committee
- Stability committee
- Pharmacology committee
- Bioequivalence committee:

Assessment procedure and timelines

The timeline for the renewal approval can be from 12 up-to 24 months. (48); (58); (59)
3.2.2.2. Iraq

In Iraq there is a special situation, that two authorities are responsible for all drug related issues. The Iraqi Directorate of Technical Affairs (DTA) as part of the MoH is responsible for all medicinal products authorized and marketed in Iraq.

For the Kurdish autonomous region, the KMCA in Erbil is responsible for the assessment of renewal applications.

Legal Basic

The legal basis for the renewal of marketing authorizations in Iraq is two important guidelines, which describes the renewal process in Iraq.

A marketing authorization in Iraq has to be renewed every five years for imported products and every 10 years for medicinal products manufactured locally. (60)

Required documents

The renewal application must be submitted three months before the expiry date of the marketing authorization. The product can be still placed on the market after submission of the renewal application. (61)

The documents have to be sending out to the Directorate of Technical Affairs (DTA) as hard and soft copies. For the submission, an application form is not required. Instead of this, the manufacturer has to insert the following document: (60)

- Declaration that the composition of the finished product has not been changed.
- checklist for renewal application [Annex X - Renewal Checklist – Iraq]
- CPP from COO or CPP from one reference country and a letter from the Iraqi National Laboratory - This letter should confirm that the finished product has pass all required testing for the last five batches. In this case, it is allowed to import the medicinal product upon one year until the requirements are fulfilled. (60)

The other requirements for renewal application are the same as for an initial marketing authorization. (60)

Assessment procedure and timelines
The DTA will start the assessment of the renewal application after receipt of all required documents. A detailed description of the procedure is not available. For the timeline of renewal, there is no timeline available.

### 3.2.2.3. Kurdistan

The KMCA in Erbil is responsible for the assessment of renewal applications in the Kurdish autonomous area in Iraq it is required to submit two samples of the medicinal product.

#### Legal Basis

The authority published a guidance document, which includes all relevant information for renewal applications of medicinal products authorized in Kurdistan. (62)

According to the Guideline, a marketing authorization has to be renewed every 5 years. (62)

#### Required documents

Additionally the following documents are required: (62)

- Original CPP from the country of origin of the manufacturer legalized by the chamber of commerce and the Iraqi embassy in the country of origin.
- Product composition certificate signed and stamped by the manufacturer;
- Finished product specifications signed and stamped by the manufacturer;
- Specifications of active and inactive ingredients signed and stamped by the manufacturer;
- Letter from the manufacturer company declaring that there are no changes made on the formula, manufacturing method and the specifications of active and inactive ingredient and finished product;
- Proof of payment of the registration fees.

### 3.2.2.4. Iran

#### Legal basis

The renewal process for medicinal products authorized in Iran is stated in the law No. D/1243 dated 9th April 2009 by the Ministry of Health & Medical Education (63) and
the “GUIDELINES ON REGISTRATION OF PHARMACEUTICAL PRODUCTS FOR IMPORTS” provide the legal basis for renewal applications for medicinal products authorized in Iran. (42)

A marketing authorization of a medicinal product in Iran is valid for 4 years. (42)

The renewal application has to be submitted within six months before the marketing authorization expires. (63); (42)

Required documents

For the renewal dossier it is required to include the following documents: (42)

- Letter of authorization (in copy)
- Valid Representation Registration Certificate issued by the Iranian Ministry of Commerce
- Certificate of a pharmaceutical Product (CPP)
- A photocopy of the Responsible Pharmacist’s license
- The bank receipt for license renewing fee
- A photocopy of the existing Marketing Authorization License
- An approval issued by the Product License Holder (PLH) or its Marketing Authorization Holder (MAH) on non-variation in the formulation, manufacturing methods and manufacturing site, and etc. of the medicine in question
- A sample of the packaging (including the box, label, strip, cartridge or vial, carton labeling or shrink-wrap)
- A specimen of the product
- The latest approval of the Division of Quality Control Laboratory of Deputy for Food and Drug on the imported consignment of the medicine in question

Assessment procedure and timelines

The Iranian MOHME does not publish any information about the assessment procedure and the timelines for approval.
3.2.2.5. Israel

Legal basis

The basis for the requirement of renewal processes of medicinal product in Israel is stated in the “Pharmacist Regulations for Medicinal products” from 1986. (64)

Additionally, the Guideline EX 005/02 from 2016 includes all processes for renewal applications in Israel. (65)

Required documents

Medicinal products, which were authorized and marketed in Israel has to be renewed every 5 years for the first time. In the Guideline it is stated:

“The director is authorized to renew the validity of a registration of a medicinal product in the Drug Registry for additional period, each of which is not longer than ten years, after the expiration of the registration in the Registry.” (65)

The renewal follows two steps

1. At first, the MAH has to request a renewal of the “quality certificate” to the Institute of Standardization and Control of Pharmaceuticals in Jerusalem.

The Institute of Standardization checks the quantitative and qualitative composition of the medicinal product against the approved specification. After a positive outcome, the Institute certify, that the medicinal product meets the required standards. (65)

Submission

The renewal dossier for the quality certificate should be submitted as CTD dossier according to the ICH-M5 Guideline (65). The following parts of the dossier are required:

Module 1:

- Checklist for submission of renewal application (for chemical entities and biological.
  - [Annex XI – Application Form for renewal of chemical entities - Israel]
  - [Annex XII - Renewal Checklist for Biologicals – Israel]
- Cover Letter
Maintenance of Marketing Authorizations in the MENA Region

- Proof of Payment
- Valid GMP certificate
- QP approval for the active ingredient
- TSE statement
- CEP
- Certificate of Analysis for the drug substance and the finished product
- Valid MSDS for the active substance and excipients
- Currently approved SmPC & PIL
- Summary of validation status and information about the medicinal product for chemical entities

Module 3:

For the first renewal, it is required to submit all documents from this part of the CTD. For the next renewal applications the Institute required a reduced Module 3 which should include the following documents: (65)

- specifications for drug substance and finished medicinal product
- stability data from the last 5 years
- significant Type II Variations - If significant variations (variations of type II that require the replacement of entire chapters in the registration file) occurred since the last renewal and the version of the file at the Institute does not correspond to the file in the hands of the MAH as a result of that, a complete updated file should be filed at the time of renewal.
- For any submission of a complete file a signed statement by the Appointed Pharmacist stating that the submitted file does not contain any non-reported changes or changes not approved by the Ministry of Health should be attached.

The file evaluator is authorized to request the submission of the complete file at his/her own discretion, even if it is not the first renewal.

Assessment procedure and timelines

Information about the assessment process and the timeline for the approval of a renewal application are not published.
3.2.2.6. Jordan

Legal Basis

In Jordan, the renewal application is regulated in the Jordan Law No. 12 of 2013, the Criteria for Drug Registration from 2015 and Circular No. 2/9/1/12448 of 2015. (43) (44)

A renewal application should be submitted every 5 years. (66) The applicant should submit the dossier within 3 months after expiry of the marketing authorization. Every year, the JFDA informs the local representatives with a list of all renewed products about the upcoming renewals.

Required documents

For the first renewal of a medicinal product, the JFDA requires the following documents, which have to be submitted in a CTD structure.

The following documents has to be included in the renewal application (43)

Module 1:

- Cover Letter from local representative, the Marketing Authorization holder or manufacturer
- Cover Letter from of the technical manager of the company or the responsible pharmacist.
- Application form - [Annex XIII - Renewal Checklist – Application form for Marketing and Renewal Application - Jordan]
- Comparison table between registration file for initial registration and re-registration dossier
- List of all ingredients (human or animal origins) including all relevant certificates
- Confirmation letter from manufacturer that the manufacturing processes does not change
- Approval letters from JFDA about all post approval changes
- Technical agreement
- Product Information and approved artworks
Maintenance of Marketing Authorizations in the MENA Region

- Summary of Product Characteristics (legalized from the NCA) of the country of origin
- Price certificate

Module 3:

- Drug composition
- Shelf life specification of the drug substance
- Certificate of Analysis of the finished product
- Stability Studies

Module 5:

- Periodic Safety Update Reports (PSUR)

If it is not the first renewal, the applicant has only to submit a legalized CPP of the COO and a price certificate.

Assessment procedure and timelines

There are no specific timelines for the renewal. According to the information of the authority it can take around two years for the assessment of the renewal.
3.2.2.7. Lebanon

Legal basis

The Decision 528/2017 and 293/2017 provides the basis for the requirement for the renewal (re-registration) of marketing authorization of medicinal products in Lebanon. (49); (50)

Since 2017 it is required for MAH to submit a renewal application for all registered medicinal products to the MoPH (Ministry of Public Health). The Technical Committee of the MoPH is responsible for all issues related to registrations of medicinal products.

The Marketing authorization will be cancelled, if the MAH does not submit a re-registration dossier for all registered medicinal products to the MoPH. Additionally the applicant has to provide a renewal plan with information about the importance of the affected medicinal products for Lebanon, the date of the registration and the countries, where the manufacturing takes place.

For renewal applications where the submission dossier is not completed until the 31\textsuperscript{th} December 2017, the marketing authorization will be on hold. This has the consequence that it’s forbidden to bring these medicinal products to the market. They will be listed as “non-marketed drugs” (49); (50)

In a Memorandum from 2016, the Ministry stated that the new re-registration process is still ongoing. Therefore it is not possible to give a timeline and procedure about the renewal process.
3.2.2.8. West Bank

Legal Basis

According to the Guidance document “GUIDANCE ON PHARMACEUTICAL PRODUCTS REGISTRATION IN PALESTINE” from 2007, a marketing authorization for a medicinal product has to be renewed every 5 years. (67)

The renewal application has to be submitted at least 4 months before the MA expires to the Drug Control and Registration Department of the MoH. It is possible to submit the application later, but if the submission will be performed more than 2 months after expiration date of the MA, the MA will be suspended.

Required documents

The application shall include the following: (67)

- Application form for the renewal – [Annex XIV – Application Form for Renewal - Palestine]
- Proof of Payment
- Approved method of analysis for the finished medicinal product
- Specification of the finished product
- Current master formula for the product
- Current stability study (Shelf life study)
- Sufficient samples for analysis accompanied by a reference standard material from the active constituent(s). Palestinian National Authority General Directorate of Pharmacy Ministry of Health Drug Control and Registration Dept DC 002-0 37 December 2007
- Samples from the latest secondary packaging materials and from the aluminum foil primary packaging material.

Assessment procedures and timelines

The Department of Drug Control and Registration reserves the right to ask for any additional documents with regard to the registered drug file.

A timeline for the procedure and an overview about the assessment report are not available.
3.2.3. Renewal application in the Maghreb States

3.2.3.1. Morocco

Legal basis

In Morocco, the following laws mention the obligatory and requirement for the renewal of marketing authorizations of medicinal product:

- Law No. 17-04: Code of Medicine and Pharmacy; (68)
- Circular No. 48 DMP/00: Procedure for the Marketing Authorization Application of Pharmaceutical Products; (45)

A marketing authorization of a medicinal product has to be renewed every 5 years. The local contact of the MAH has to submit a renewal dossier 180 days before the marketing authorization expires. For medicinal products imported from outside the marketing authorization has to be valid in the COO as well. (45)

Required documents

Concerning the submission of the renewal application, the DMP differs between the first renewal application and the following renewal applications. For the first review, the applicant has to submit a full CTD dossier of a medicinal product except of Module 4 (Non-clinical) and Module 5 (Clinical).

It is required to submit two application forms (45)

- “DMP” application form – [Annex XV – DMP Application Form for Renewal - Morocco]

For the following renewal applications, it is only required to submit a cover letter, which states that the marketing authorization will be renewed. (45)

Assessment procedure and timelines

The assessment of the renewal application will be submitted to the DMP. The review of the quality part of the dossier will be done by the LNCM and the administrative review by the DMP. Within 6 months, the marketing application will be renewed.
3.2.3.2. Algeria

Legal Basis

The legal basis for the renewal of marketing authorization is the Decree No. 92-284 of 1992. (46)

In Algeria a marketing authorization of a medicinal product has to be renewed every 5 years. The submission of the renewal has to be done at earliest in 6 months and at latest in 3 month by the local agent of the MAH before the marketing authorization expires to the ANPP. (46)

Required documents

The ANPP differs between two types of scenario: (46)

1. In case that the dossier of the initial registration does not changed or if all variations were submitted on-time (which means that the dossier is at the time of renewal up-to-date), the applicant has to submit the following documents
   - Statement of the MAH, that the content of the technical information of the medicinal product has not been changed since the first registration
   - Proof of payment of the registration fees (also from variations which were submitted in the last five years)
   - legalized CPP from the country of the MAH

2. In case, that the current dossier of the medicinal product does not correspond to the initial registration dossier or if variations were not submitted previous the following dossier requirements has to be fulfilled
   - Renewal letter (2 copies) and statement from MAH (3 copies) that the changes of the medicinal product were approved.
   - Submission receipts of variations
   - Checklist list of local application form
   - Form A (legalized) –
     - Annex XVIII – Annex A Application Form for Renewal - Algeria
     - Annex XVII – Application Form for Renewal - Algeria
     - Annex XIX – Annex II Application Form for Renewal - Algeria
   - CPP and/or marketing authorization Approval letters with annexes issued by the country, where the MAH is stated
• Manufacturing license for all sites involved in drug product manufacturing.
• GMP certificates for all sites participating in the drug product manufacturing.
• Free On Board (FOB) price attestation
• Therapeutic information form
• 1 finished product sample along with the corresponding original certificate of analysis;
• Copies of certificate of analysis for the active ingredient and excipients;
• Updated soft copy of the Common Technical Document (CTD) Module 3 (no hard copy is needed; only a CD/DVD) in addition to the updated labelling and summary of product characteristics;
• Proof of payment of the registration fees;
• Authenticated certificate of suitability (CoS) or Drug Master File (DMF) with letter of access;
• Statement mentioning all the parties involved in the product manufacturing;
• Copy of the Active Pharmaceutical Ingredient (API) GMP certificate;
• Variation forms signed and stamped by the MAH.

Legalization of required documents has to be done by the Chamber of Commerce, by the Ministry of Foreign Affairs and by the Algerian embassy in the country of origin of the MAH)

Assessment procedure and timelines

The renewal will be assessed within three to six months by the ANPP. (46)
3.2.3.3. Tunisia

Legal basis

In the Tunisian Law No. 85-91 from 1985 the requirement for MAH to renew the marketing authorization of medicinal products marketed in Tunisian is included. (69)

Additionally the Order from the MoH from 1996 describes the obligation and requirements for a renewal application in Tunisia. (70)

A marketing authorization in Tunis is valid for 5 years. A renewal application has to be submitted by the local contact point of the MAH 6 month before expiry date (51).

Required documents

The Tunisian law divides the requirement of the renewal application into two subgroups.

For medicinal products manufactured in Tunisia the following documents has to be included in the renewal application: (51).

- Cover letter
- Application sheet in French signed by the applicant responsible pharmacist
- A Certificate from the responsible pharmacist of the company attesting that there is no change in the medicinal product files that had been submitted for the initial registration
- GMP certificate of manufacturing sites for the finished product
- Updated SmPC (Word and PDF versions)
- Proof of payment for the renewal fee
- Two samples of the medicinal products (Tunisian market sale model) accompanied by their certificate of analysis.

For medicinal products imported into Tunisia, the above mentioned documents have to be submitted too. Additionally it is required to submit: (51)

- Copy of the updated Marketing authorization in the country of origin (COO)
- CPP from COO
Maintenance of Marketing Authorizations in the MENA Region

- Approved SmPC in the country of origin (COO)
- Two sale model samples (Country of origin market) and the corresponding certificates of analysis
- Certificate of wholesale price excluding issued by competent authorities in the country of origin.

Procedure and timelines

The timeline for the renewal assessment is due within 15 days. (51)
3.2. Other procedure to maintain a marketing authorization of a medicinal product in the MENA region

In all countries of the MENA region, a marketing authorization of a medicinal product will be suspended, if the benefit-risk relation is negative and if there are high risks for the public health.

A MA for a medicinal product can be withdrawn, if the qualitative and quantitative composition of the finished drug product does not fit with the specification submitted within the application for marketing authorization or if the documents provided in the initial registration are not in line with the manufacturing and pharmaceutical profile of the medicinal product. In some countries, it is required that at least 2 of 3 batches have to be compliant with the approved drug specification; otherwise the MA will be withdrawn by the NCA.

For imported medicinal products, it is required that the MA in the COO is still valid. Otherwise this could be an entitled reason to withdrawn the marketing authorization in the affected country.

Additionally a large number of MENA countries implement regulations, which defined that if the medicinal product is not placed on the market over a certain period, the marketing authorization will be cancelled.

This procedure is well known in the European countries as “Sunset Clause”. The EMA defines the term as follows:

“The so-called "sunset clause" is a provision leading to the cessation of the validity of the marketing authorization…” (71)

The EMA differs between two possible scenarios to withdrawn a marketing authorization according to Sunset Clause: (71)

- if the medicinal product was not placed in the market within three years after the initial marketing authorization.
- if the medicinal products is not marketed for three years

Many countries of the MENA region implement similar rules, but in the opposite to the Member States of the European Union, the marketing authorization will be cancelled, if the medicinal product is not marketed within a defined period of time after getting
the approval for MA. Only in a few countries of the Levant states and in Morocco, there are also other defined requirements to obtain a MA in these countries.

For medicinal products registered centrally in the GCC States, a marketing authorization can be withdrawn if the medicinal product is not placed on the market within two years after approval. It is required that the medicinal product is marketed at least in two countries of the GCC otherwise the marketing license will be suspended. (72)

The following tables provide an overview about existing rules regarding sunset clause in each country.

### 3.2.1. Gulf States

Table 1: Overview about Sunset Clause in the Gulf States

<table>
<thead>
<tr>
<th>Country</th>
<th>Sunset available [Yes/No]</th>
<th>Timelines</th>
<th>Other requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>KSA</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>UAE</td>
<td>Yes</td>
<td>12 months</td>
<td>- Medicinal product has to be marketed within 12 months after registration</td>
</tr>
<tr>
<td>Bahrain</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Oman</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| Qatar   | Yes                      | 3 months  | - Sunset clause for GCC  
- Pharmaceutical company does not marketed registered products for 3 months (the registration of the pharmaceutical company will be withdrawn) (40) |
| Kuwait  | Yes                      | 2 years   | - Medicinal product is |
3.2.2. Levant States

Table 2: Overview about Sunset Clause in the Levant States

<table>
<thead>
<tr>
<th>Country</th>
<th>Sunset available [Yes/No]</th>
<th>Timelines</th>
<th>Other requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egypt</td>
<td>Yes</td>
<td>18 months</td>
<td>- product has to be manufactured locally within 18 months (41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 years</td>
<td>- product has to be manufactured or imported within 2 years from expiry date of the last batch (41)</td>
</tr>
<tr>
<td>Iraq</td>
<td>Yes</td>
<td>1 year</td>
<td>Medicinal product has to be marketed within 1 year after initial MAA (73)</td>
</tr>
<tr>
<td>Kurdistan</td>
<td>Yes</td>
<td>1 year</td>
<td>- Same requirement as in Iraq (73)</td>
</tr>
<tr>
<td>Iran</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Israel</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Jordan</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Lebanon</td>
<td>Yes</td>
<td>1 year</td>
<td>- product has to be marketed within 1 year after registration (74)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- if the sales of a medicinal product is very low, the MAA can be cancelled</td>
</tr>
</tbody>
</table>
### 3.2.3. Maghreb States

Table 3: Overview about Sunset Clause in the Maghreb States

<table>
<thead>
<tr>
<th>Country</th>
<th>Sunset available [Yes/No]</th>
<th>Timelines</th>
<th>Other requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morocco</td>
<td>Yes</td>
<td>-12 months - 6 months</td>
<td>- medicinal product has to be marketed within 1 year of obtaining a license</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- continuous supply of goods over 6 months and maintenance of safety stock required</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(75)</td>
</tr>
<tr>
<td>Algeria</td>
<td>Yes</td>
<td>12 months</td>
<td>- medicinal product has to be placed on marketed within 1 year after registration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(46)</td>
</tr>
<tr>
<td>Tunisia</td>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
3.3. Harmonization of renewal procedure in MENA region

Inside the MENA region, there are three subgroups, but only the Gulf States has
developed a central renewal procedure for marketing authorizations.

Legal Basis

In Article 29A of the “Executive Board of the Health Ministers’ Council For GCC”, a marketing authorization for a centrally registered medicinal product in the GCC region is valid for 5 years. (76)

In case that the medicinal product was centrally approved by the GCC-Drug Registration Committee (GCC-DR), the renewal application has to be submitted within 3 months before the marketing authorization expires. (76)

Required documents

For products, which were authorized centrally via GCC-DR, it is not obligatory, that a local contact has to submit the application to the authority. The marketing license will be cancelled, if the applicant fails to submit a renewal application within 6-months after the expiry of the MA.

The following documents should be submitted to the committee of the GCC-DR, which is responsible for renewal of medicinal products: (76)

- Application form
- CPP or certificate of free sale legalized by the NCA of the COO
- List of manufacturers including the countries, who handle the medicinal product
- List of countries, where the product is
  - authorized
  - not authorized and the reasons
- Currently Approved EN version of the SmPC or PIL from COO (approved by the NCA of the COO)
- List of all approved variations and re-registration applications
- Declaration form MAH, that there is no change of the medicinal products. In case of any changes of the medicinal products (quality, safety or efficacy
related), the applicant has to submit the changes together with the re-registration dossier

- Update of Stability data and stability study for two batches
- Certificate of Suitability
- Drug Master File from Manufacturer (in case, if CEP is not available)
- Methods of analysis for finished product according to the last approved Pharmacopeia
- Certificate of Analysis for finished medicinal products
- result of follow-up studies the product-marketing
- Commercial Samples
- Sample or Artwork for External Package

For biologicals or herbal medicinal products, the Committee required the following documentation additionally:

- Microbial Contamination Test for oral solutions (if one of the excipients are animal or plant origin

Assessment procedure and timelines

The timelines for the approval of a renewal application and the assessment procedure were not communicated by the GCC-DR.
4. Differences and Similarities to European Procedures

The previous part describes the renewal procedures and maintenance procedures of MA in the MENA countries.

For pharmaceutical companies located in Europe, it’s more interesting to know the similarities and differences to known European Procedures.

4.1 Renewal procedure for medicinal products authorized via CP, DCP and MRP in the European Union

To get a better overview about the differences and similarities of maintenance procedures of MAA between the countries of the European Union and the MENA region, it is important to get an overview about renewal procedures for medicinal products authorized in the Member States of the European Union. In Europe there are three possible procedures to receive a MA for a medicinal product in the member states of the EU.

4.1.1 Centralized procedure

The centralized procedure allows medicinal products to receive MAA in all Member States of the EU. For drug substances against cancer, metabolic diseases, infectious diseases, and biologicals, it is required to submit an application for MA via the centralized procedure.

Legal framework

In the European regulation EC 726/2004 it is stated, that a MA for medicinal products authorized via CP is valid for 5 years. The EMA Guideline “Guideline on the processing of renewals in the centralised procedure” describes the renewal process for CP products. (77)

The applicant has to submit a renewal application to the EMA within 9 months, before the MAA expires. It is required, that the Applicant appoints a submission date to the EMA. This step is important, because the EMA has to agree the proposed submission date with the Rapporteur and Co-Rapporteurs. (77)
Maintenance of Marketing Authorizations in the MENA Region

Required documents

The Applicant has to submit Module 1 and Module 2 of the dossier. Module 2 contains the Quality Addendum, Non-clinical and Clinical Addendum. The Risk-Management Plan has to be included in the dossier too. (77)

All required documents are listed in Annex XX – Required documents for renewal of CP products

It is possible to include changes in the renewal application. This has to be stated in the application form. If new clinical studies are available, it is obligatory to submit the data within the renewal application. (77)

Assessment procedure and timelines

The CHMP and the PRAC are involved in the assessment of a renewal application for a medicinal product. If the Rapporteur and Co-Rapporteur agree, that the benefit risk evaluation is positive, the CHMP recommend a positive opinion. This means that the MAA will get either an unlimited validity or validity for five years.

If the CHMP comes to the output, that the benefit risk evaluation is not positive and that the medicinal product has a potential risk for the public health, the Committee will adopt an “unfavorable” opinion. The MAA will suspend and be withdrawn from the European Market. (77)

The EMA will prepare an update of the European Public Assessment Report (EPAR), reflecting the renewal assessment and CHMP opinion. After the Commission Decision on the renewal, the updated EPAR shall be published.

The renewal process takes 120 days. (77)
4.1.2 Decentralized procedure/Mutual recognition procedure

The DCP and MRP procedures are two other options to authorize a medicinal product in countries of the European Union. In opposite of the centralized procedure, the MAH can select in which countries

Legal Basis

In Article 24 of the European Directive 2001/83/EC, it is stated that a MAA for a medicinal product is valid for five years. If the the MAA is renewed for once, the validity will be unlimited. The “Guideline on the Processing of the Renewals in the Mutual Recognition and Decentralized Procedure” describes the renewal process for medicinal products, which were authorized via DCP or MRP. There is no difference between the renewal application of medicinal products authorized via DCP or MRP.

The Applicant has to submit the renewal application within six months before the MAA expires. It is important that the Applicant agrees a “common” renewal date with all Member States, which were involved in the process.

Required documents

As for the renewal application for MAA authorized via Centralized Procedure, the Applicant has to submit the whole documentation of Module 1 and Module 2 (see Annex XXI – Required documents for renewal of DCP or MRP products).

The dossier should be submitted in eCTD.

If Applicant wants to implement new amendments in the Product Information, it has to be discussed and agreed with the RMS before submission.

Assessment procedure and timelines

The aim of the renewal application is to assess the benefit-risk evaluation of a medicinal product based on new information and on PSURs.

During the renewal procedure, variations should not be included in the renewal procedures. However it is permitted to include administrative changes of the Product Information together in this procedure. The changes need to be listed in the application form (see Annex). It is recommended to discuss proposed amendments
Maintenance of Marketing Authorizations in the MENA Region

of the SmPC together with the responsible RMS before submission of the renewal application.

The timeline for a renewal for medicinal products authorized via DCP or MRP is around 90 days. During this time, a clock-stop period is possible. The Applicant may send further documentation to the RMS & CMS upon request within 30 days after the start of the clock-stop period.

It is possible to submit a “shortened” renewal application. This will follow a 30 days procedure. In this case, a clock-stop is not possible and the RMS will leads the assessment of the renewal.

After the first renewal, the MA will have an unlimited validity. In some exceptions, it is possible that the RMS required a renewal after 5 years.

4.1.4. Other maintenance procedures in the European Union

To maintain a MA for a medicinal product in the EU, it is required to obtain the sunset clause for medicinal products authorized under regulation 2001/83/EC.

For centrally authorized medicinal products it is stated in Article 14 of the regulation 726/2004 and in Article 24 of the regulation 2001/83/EC, [which is also valid for medicinal products authorized via DCP or MRP], it is stated that a MA will be valid, if one presentation of the medicinal product is placed on the market. If a medicinal product is not marketed within 3 years in any Member State of the EU (including the EEA States as Norway, Island and Lichtenstein) the MA will be withdrawn from the pharmaceutical market. (79)
4.2. Differences and Similarities between the procedures in the MENA Region and the European Union

In the previous parts of this master thesis, several procedures to maintain a MAA in the MENA region and the European Union were discussed. The differences and similarities will be shown in detail.

Validity

All MA in European countries and in the MENA countries have a validity of 5 years, except Iran, where a MA for medicinal products is valid for 4 years. (42)

The main difference is if the first renewal application for a MAA authorized via CP, DCP or MRP is positive, the MAA has an unlimited validity. But this comes with an exception, except for medicinal products, which were authorized under “conditional approval or exceptional circumstances”. For these products, they have to be renewed again.

All NCA’s of the MENA countries require a renewal application for every five years. That also applies, even the qualitative and quantitative composition of the medicinal products does not change or the benefit-risk evaluation remains the same as in the initial application.

Date of Renewal

To maintain a MAA via a renewal application, applicant has to submit the dossier within 9 months for medicinal products authorized via CP, and 6 months for medicinal products authorized via DCP or MRP. In the MENA region, the timelines for renewal are quite different.

A majority of the MENA countries have a renewal timeline of 6 months before expiration of the MA. In several countries the renewal application should be submitted within 3 months.

Required documents

The Applicant has to submit the Module 1 and Module 2 of the CTD to the Authorities for renewal application of European MAA.
In most cases, the NCA of nearly all countries of the MENA region requires documents from Module 1 and Module 3. The overall summaries of the quality, non-clinical and clinical part are not part of the assessment of the benefit-risk evaluation. The European CA does not require documents for Module 3, only on request.

This is a main difference between MENA and Europe, because the assessment of a renewal application based on information provided in Module 2. For NCA of the MENA region, the assessors are focused on data based on the CMC part of a dossier, because most of variations affect the quality of a medicinal product. The assessment of the benefit-risk evaluation based on the summaries provided in Module 2 is not sufficient for the NCA of the MENA region.

For the GCC and Levant States another possible reason could be that the data in Module 3 should improve, that the current manufacturing processes, the analysis and the specifications are up-to-date and not been changed without a corresponding notification to the authority. This fact could be seen as “additional” control from the NCA to avoid medicinal products with content which were not approved by the authorities.

This “additional control” could also be a possible reason, why the applicant has to provide a list of all submitted variations including the approvals of the NCA. It can be seen as further measures against corruption, because the MAH’s and manufacturers cannot implement changes in the quality and quantity of a medicinal product without approval of the Authorities. This also indicates that the confidence of the Authorities to the manufacturers and MAH’s is not stabilized enough and it can be disassembled.

For imported products or medicinal products, where the MAH is stated outside the affected country, the applicant has to indicate that a MAA is still valid in the COO. This can usually be done by submitting a CPP either from the origin country of the MAH (if outside the affected country) or of the country where the manufacturing takes place. In some countries it is also required to submit a list of all valid MAA in the world of the relevant medicinal product. For European renewal procedures, a CPP is not required for submission. Most of the medicinal products authorized in the MENA region are mostly imported from European countries and the USA. On the one sid the initial applications for new drug substances will be done in these countries. Most of the MAH are located there, the development of potential new drug substances takes
place there and both markets rank among the most important markets for pharmaceuticals in the world.

On the other side the development of innovative medicinal products in the MENA region is not on the same level as in USA, Europe or Japan. The missing innovations and regulations for potential new drugs are still under development and it will take decades to reach the same level regarding development and marketing of medicinal products as the EU, USA and Japan.

The format of the submission dossier is another point, which should be considered. This point indicates only exceedingly few differences. Most of the MENA countries require a CTD according to ICH-M4 as in the European countries. Only in Lebanon and Egypt, a submission of the dossier as CTD format is still not possible. The dossier language is English, except in the Maghreb States. In these countries, the applicant has to provide the documents in French.

Assessment procedure

The assessment of renewal applications for European MAA is quite simple. The benefit-risk evaluation will be assessed based on the overall summaries. For NCA from MENA, the assessors evaluate the benefit-risk evaluation based on the data mainly provided from Module 3.

The difference in the approach of an assessment of a renewal application could be, that most of the NCA in the MENA region are relative “young” in opposite to the European NCA and not so much experienced with renewal application. In several countries, such as Lebanon, the obligatory for MAH to renew the MAA of their products was introduced in 2017 and also the renewal procedure for medicinal products authorized via centralized procedure of the GCC-DR is not as long as in Europe.

Another important point to consider is, the NCA of the MENA countries included other activities (eg. inspection of the local manufacturing) in the assessment of the renewal process. For European procedures, an inspection during a renewal procedure is not required. This additional inspection is time consuming and cause longer periods for the assessment of renewal applications.
In opposite to the renewal procedures for marketing authorizations granted via CP, DCP or MRP, the applicant cannot submit variations within the renewal applications. The authorities recommend that all important variations, which may have an impact on the safety, efficacy and quality of a medicinal product, should be submitted and approved prior to the renewal application. This is also a reason, why the applicant has to submit all variations, which were submitted and approved prior to the renewal application- due to the fact that the Authorities try to avoid additional workload during the renewal process. Another plausible reason could be, that the NCA does not have enough resources for the assessment of variations and renewal application on the same time.

Timelines

For renewal application for CP, DCP or MRP products the timeline is 120 days. This consists of 90 days of assessment for the authorities and 30 days as “clock-stop”.

Sunset clause

To maintain a MA for a medicinal product via Sunset clause exist for all European procedures and for the MENA countries. The requirements are nearly the same, except in Lebanon. The special situation there is that if the sales numbers for a medicinal product are not high enough, the product will be withdrawn from the market.
### Table 4: Differences and Similiarities between EU and MENA

<table>
<thead>
<tr>
<th></th>
<th>Renewal MA – EU</th>
<th>Renewal MA – MENA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Validity</strong></td>
<td>5 years for initial MAA, unlimited validity after renewal* (Iran 4 years)</td>
<td>Every 5 years</td>
</tr>
<tr>
<td><strong>Renewal Date</strong></td>
<td>9 months for CP products 6 months for DCP/MRP products</td>
<td>3 – 6 months</td>
</tr>
<tr>
<td><strong>Important requirement</strong></td>
<td>N/A</td>
<td>Valid MAA in COO</td>
</tr>
<tr>
<td><strong>Required documents</strong></td>
<td>Module 1 Module 2</td>
<td>Module 1 Module 3 Module 4 Module 5</td>
</tr>
<tr>
<td></td>
<td>• Documents will be provided in English language</td>
<td>• Documents will be provided in English language (except Maghreb States**)</td>
</tr>
<tr>
<td><strong>Assessment</strong></td>
<td>Assessment of benefit-risk evaluation</td>
<td>Assessment of benefit-risk evaluation</td>
</tr>
<tr>
<td><strong>Submission</strong></td>
<td>EU- e-CTD (no paper submission)</td>
<td>CTD (hard copy and soft copy), additional paper submission optional</td>
</tr>
<tr>
<td><strong>Timelines</strong></td>
<td>120 days (90 days assessment + 30 days clock-stop) - CP 90 days (DCP/MRP)</td>
<td>15 days – 24 months</td>
</tr>
<tr>
<td><strong>Inclusion of other applications within renewal?</strong></td>
<td>Yes • variation can be included within renewal application (for CP)</td>
<td>No • variations cannot be included within renewal application</td>
</tr>
<tr>
<td><strong>Mock-ups required</strong></td>
<td>No</td>
<td>Yes (not for all MENA countries)</td>
</tr>
<tr>
<td><strong>Shortened renewal applicable?</strong></td>
<td>Yes (for DCP/MRP)</td>
<td>No (except Morocco)</td>
</tr>
<tr>
<td><strong>Sunset clause available</strong></td>
<td>Yes</td>
<td>Yes except</td>
</tr>
</tbody>
</table>

* except for medicinal products authorized under “conditional approval” or “Exceptional circumstances”

** documentation should be provided in French
5. Summary, Discussion and Outlook

The detailed reflection of procedures in the MENA region to maintain a marketing authorization for a medicinal product shows, that the regulatory affairs for medicinal products is in an ongoing process. During the time, many authorities in the MENA try to improve the procedures and regulations for pharmaceuticals. Especially due to the increased need of medicinal products and the development of the pharmaceutical sectors of local and private manufacturers, the authorities and institutions develop and improve existing laws and regulation to facilitate the post-authorization procedures in the MENA region.

On the other side this master-thesis also shows, that many NCA in the MENA region are still not enough regulated. Many issues need to be improved in future as the transparency and timelines for renewal procedures in the relevant countries.

The renewal applications for medicinal products authorized in the MENA region are (dependent from the country) very demanding. All NCA’s in the region requires further renewal applications of a medicinal products, even the quality and the composition of the medicinal product does not changed.

These further renewal applications are not necessary, due to the fact, that neither the composition nor the quality of a medicinal product changed. Additionally the assessment of a renewal application is not transparent; in some countries as in Tunisia, the renewal application takes only 15 days, in Egypt the assessment can take up to 2 years.

There are some similarities between the European procedures and the procedures in the MENA region. Nearly all MENA countries, except Egypt and Lebanon, require a CTD dossier, in the Gulf States a submission even as eCTD is mandatory.

The main difference between European procedures and MENA procedures for renewal applications is the required documents.

Whereas the European HA’s require the submission of Module 2, which contains the overall summaries for the quality, non-clinical and clinical part of a dossier, none of the HA’s in the MENA region requires documentation from Module 2. In some countries, it is obligatory to include documents from Module 4 and Module 5 into the renewal application.
Maintenance of Marketing Authorizations in the MENA Region

The most of the authorities in the MENA require the submission of documents from Module 3. These documents will not be provided to the European HA’s at time of renewal.

Regarding sunset clause, there requirements for medicinal products authorized in Europe or in the MENA region are nearly the same. In this case it is interesting to see, that a medicinal product can be withdrawn from the Lebanese pharmaceutical market, if the sales numbers are not high enough, even the medicinal product is placed on the market.

The maintenance procedures in the MENA are very individual and none of the countries accept the approval of a renewal from another MENA country, especially for the Levant and Maghreb States. For these subgroups, there are no “recognition” procedures for renewal applications. In this case the Gulf States are further developed, because it is possible to maintain one MA for a medicinal product, centralized via GCC-DR. The renewal for a MA is valid for all member of the GCC.

The objective of this thesis shows, how demanding the MENA region is. Especially for small and medium enterprises it is very difficult to authorize and maintain a MA for a medicinal product, due to the fact that besides the high request of documents, a local agent is required for all countries of the MENA region. Only in case of a centrally MA via GCC-DR, a local agent is not necessary.

In the author’s point of view, the pharmaceutical sector of the MENA countries and the maintenance procedures for MA of medicinal products are in development and it can be expected with great confidence, that the regulatory procedures will be much better as today.
List of References


Maintenance of Marketing Authorizations in the MENA Region


35. TOPRA MSc Module 1 – Strategic Planning in Regulatory Affairs. Regulatory Strategy for the Emerging Markets - Far East, Africa, Middle East, Latin America. [Online] [Cited: April 24, 2018.]


42. Ministry of Health & Medical Education. GUIDELINES ON REGISTRATION OF PHARMACEUTICAL PRODUCTS FOR IMPORTS In the Islamic Republic of Iran. [Online] April 2007. [Cited: May 26, 2018.]


57. State of Kuwait - Ministry of Health. Guidelines for registration of pharmaceutical products. [Online] [Cited: July 06, 2018.]


Maintenance of Marketing Authorizations in the MENA Region


80. Egyptian Drug Authority. [Online] [Cited: April 15, 2017.]


Annex I - Application Form for Renewal application in KSA

Application for Renew or Updating Information of Pharmaceutical Consultation Center License

All fields are mandatory except for Location coordinates
# Maintenance of Marketing Authorizations in the MENA Region

## Center Information

<table>
<thead>
<tr>
<th>Language</th>
<th>Arabic</th>
<th>English</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td>اسم المركز</td>
<td>Name (Center Name)</td>
</tr>
<tr>
<td><strong>License NO.</strong></td>
<td>رقم الترخيص</td>
<td></td>
</tr>
<tr>
<td><strong>Civil Defense License Number</strong></td>
<td>رقم ترخيص الدفاع المدني</td>
<td></td>
</tr>
<tr>
<td><strong>Expiry Date</strong></td>
<td>تاريخ انتهاء</td>
<td></td>
</tr>
<tr>
<td><strong>Municipal License Number</strong></td>
<td>رقم ترخيص البلدية</td>
<td></td>
</tr>
<tr>
<td><strong>Expiry Date</strong></td>
<td>تاريخ انتهاء</td>
<td></td>
</tr>
<tr>
<td><strong>The Center Commercial Record No.:</strong></td>
<td>رقم السجل التجاري الفرعي للمركز</td>
<td></td>
</tr>
</tbody>
</table>

## Center Address

<table>
<thead>
<tr>
<th>Language</th>
<th>Arabic</th>
<th>English</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Province</strong></td>
<td>إمارة</td>
<td></td>
</tr>
<tr>
<td><strong>City</strong></td>
<td>مدينة</td>
<td></td>
</tr>
<tr>
<td><strong>Area District</strong></td>
<td>منطقة</td>
<td></td>
</tr>
<tr>
<td><strong>Street</strong></td>
<td>شارع</td>
<td></td>
</tr>
<tr>
<td><strong>Building Number</strong></td>
<td>رقم المبنى</td>
<td></td>
</tr>
<tr>
<td><strong>Location Coordinates (GPS):</strong></td>
<td>(GPS)</td>
<td></td>
</tr>
<tr>
<td><strong>North</strong></td>
<td>شمال</td>
<td></td>
</tr>
<tr>
<td><strong>East</strong></td>
<td>شرق</td>
<td></td>
</tr>
</tbody>
</table>

## Contact Information

<table>
<thead>
<tr>
<th>Language</th>
<th>Arabic</th>
<th>English</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phone</strong></td>
<td>الهاتف</td>
<td></td>
</tr>
<tr>
<td><strong>Extension</strong></td>
<td>تحويلة</td>
<td></td>
</tr>
<tr>
<td><strong>Fax</strong></td>
<td>الفاكس</td>
<td></td>
</tr>
<tr>
<td><strong>Email</strong></td>
<td>البريد الالكتروني</td>
<td></td>
</tr>
</tbody>
</table>

## Owner Information

<table>
<thead>
<tr>
<th>Language</th>
<th>Arabic</th>
<th>English</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Establishment</strong></td>
<td>مؤسسة</td>
<td></td>
</tr>
<tr>
<td><strong>Company</strong></td>
<td>شركة</td>
<td></td>
</tr>
<tr>
<td><strong>Establishment/Company Name (in Arabic):</strong></td>
<td>اسم المؤسسة/الشركة (باللغة العربية)</td>
<td></td>
</tr>
<tr>
<td><strong>Establishment/Company Name (in English):</strong></td>
<td>اسم المؤسسة/الشركة (باللغة الإنجليزية)</td>
<td></td>
</tr>
<tr>
<td><strong>Main Commercial Record No.:</strong></td>
<td>رقم السجل التجاري الرئيسي</td>
<td></td>
</tr>
</tbody>
</table>
## Center Information

<table>
<thead>
<tr>
<th>Name (In Arabic):</th>
<th>اسم (باللغة العربية):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name (In English):</td>
<td>اسم (باللغة الإنجليزية):</td>
</tr>
<tr>
<td>License NO.:</td>
<td>رقم الترخيص:</td>
</tr>
<tr>
<td>Civil Defense License Number:</td>
<td>رقم ترخيص الدفاع المدني:</td>
</tr>
<tr>
<td>Expiry Date:</td>
<td>تاريخ انتهاء</td>
</tr>
<tr>
<td>Municipal License Number:</td>
<td>رقم ترخيص البلدية:</td>
</tr>
<tr>
<td>Expiry Date:</td>
<td>تاريخ انتهاء</td>
</tr>
<tr>
<td>The Center Commercial Record No.:</td>
<td>رقم السجل التجاري الفرعي للمركز:</td>
</tr>
</tbody>
</table>

## Center Address

| Province: | المنطقة: |
| City: | المدينة: |
| Area/ District: | الحي: |
| Street: | الشارع: |
| Building Number: | رقم المبنى: |
| Location Coordinates (GPS): | إحداثيات الموقع (GPS): |

<table>
<thead>
<tr>
<th>North</th>
<th>شرق</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Phone: | الهاتف: |
| Extension: | تمهيد: |
| Fax: | الفاكس: |
| Extension: | تمهيد: |
| Email: | البريد الإلكتروني: |
| Mailing Address: | العنوان البريدي: |

## Owner Information

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Establishment/Company Name (in Arabic):</td>
<td>اسم المؤسسة/الشركة (باللغة العربية):</td>
</tr>
<tr>
<td>Establishment/Company Name (in English):</td>
<td>اسم المؤسسة/الشركة (باللغة الإنجليزية):</td>
</tr>
<tr>
<td>Main Commercial Record No.:</td>
<td>رقم السجل التجاري الرئيسي:</td>
</tr>
</tbody>
</table>
### Establishment/Company Address

| Province: | المَتَّة | Arabic: | المَتَّة |
| City: | المدينة | Arabic: | المدينة |
| Area/District: | الحي | Arabic: | الحي |
| Street: | الشَّارِع | Arabic: | الشَّارِع |
| Building Number: | رقم المبنى | Arabic: | رقم المبنى |
| Location Coordinates (GPS): | |  | | | |
| | North | شمَّال | Arabic: | شمَّال |
| | East | شرَق | Arabic: | شرَق |

### Establishment Owner or the Specialized Partner Information

| Name: | | | |
| National ID Number: | | | |
| Expiry Date: | | | |
| Professional Registration ID No.: | | | |
| Expiry Date: | | | |
| Mobile: | | | |
| Email: | | | |

### Center Activities

- Bioequivalence & Bioavailability (BE & BA)
- Pharmaceutical/ Cosmetic Product analysis laboratory
- Drug & Poisoning Information Center (DPIC)
- Pharmacovigilance services
- Consultation

#### Only for Bioavailability & Bioavailability Studies activity

<table>
<thead>
<tr>
<th>H</th>
<th>O</th>
<th>□</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

| Clinical Analysis Laboratory | \[حلاحظة\] | □ |
| Clinics and Inpatient Rooms | □ | □ | □ | □ |

Version 3.2 - 15/12/2013

71
**Clinical Analysis Laboratory**

<table>
<thead>
<tr>
<th>Field</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td></td>
</tr>
<tr>
<td>License No.</td>
<td></td>
</tr>
<tr>
<td>Province</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td></td>
</tr>
<tr>
<td>Phone</td>
<td></td>
</tr>
<tr>
<td>Fax</td>
<td></td>
</tr>
<tr>
<td>Extension</td>
<td></td>
</tr>
<tr>
<td>Email</td>
<td></td>
</tr>
<tr>
<td>Mailing Address</td>
<td></td>
</tr>
</tbody>
</table>

**Clinics and Inpatient Rooms**

<table>
<thead>
<tr>
<th>Field</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td></td>
</tr>
<tr>
<td>License No.</td>
<td></td>
</tr>
<tr>
<td>Province</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td></td>
</tr>
<tr>
<td>Phone</td>
<td></td>
</tr>
<tr>
<td>Fax</td>
<td></td>
</tr>
<tr>
<td>Extension</td>
<td></td>
</tr>
<tr>
<td>Email</td>
<td></td>
</tr>
<tr>
<td>Mailing Address</td>
<td></td>
</tr>
</tbody>
</table>

**Center Manager Information**

<table>
<thead>
<tr>
<th>Field</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td></td>
</tr>
<tr>
<td>National ID Number</td>
<td></td>
</tr>
<tr>
<td>Expiry Date</td>
<td></td>
</tr>
<tr>
<td>Professional Registration ID No.</td>
<td></td>
</tr>
<tr>
<td>Expiry Date</td>
<td></td>
</tr>
<tr>
<td>Mobile</td>
<td></td>
</tr>
<tr>
<td>Email</td>
<td></td>
</tr>
</tbody>
</table>

*Version 3.2 - 15/12/2013*
## Maintenance of Marketing Authorizations in the MENA Region

### Only for Bioequivalence & Bioavailability Studies activity

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality:</th>
<th>National ID Iqama No.:</th>
<th>Expiry Date</th>
<th>Professional Registration ID No.:</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Responsible Person for Clinical Laboratory**

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality:</th>
<th>National ID Iqama No.:</th>
<th>Expiry Date</th>
<th>Professional Registration ID No.:</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Responsible Person for Pharmaceutical Product: Analysis in Biological Tissues**

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality:</th>
<th>National ID Iqama No.:</th>
<th>Expiry Date</th>
<th>Professional Registration ID No.:</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Responsible Person for BE & BA studies**

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality:</th>
<th>National ID Iqama No.:</th>
<th>Expiry Date</th>
<th>Professional Registration ID No.:</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Responsible Person for Quality Control**

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality:</th>
<th>National ID Iqama No.:</th>
<th>Expiry Date</th>
<th>Professional Registration ID No.:</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical/ Cosmetic Product analysis laboratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Responsible Person for Product Analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Name:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nationality:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>National ID/ Iqama No.:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Expiry Date:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professional Registration ID No.:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Expiry Date:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mobile:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Email:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Drug & Potasing Information Center**              |
| **Responsible Person for DPIC**                    |
| **Name:**                                           |
| **Nationality:**                                    |
| **National ID/ Iqama No.:**                         |
| **Expiry Date:**                                    |
| **Professional Registration ID No.:**              |
| **Expiry Date:**                                    |
| **Mobile:**                                        |
| **Email:**                                         |

| **Pharmacovigilance Services**                     |
| **Responsible Person For Pharmacovigilance Services** |
| **Name:**                                           |
| **Nationality:**                                    |
| **National ID/ Iqama No.:**                         |
| **Expiry Date:**                                    |
| **Professional Registration ID No.:**              |
| **Expiry Date:**                                    |
| **Mobile:**                                        |
| **Email:**                                         |
The official address for receiving the official letter and memos from SFDA:
Fax No.: 
Extension: 
Email: 
Mailing Address: 

Is there a delegated person to follow up with SFDA? If YES please fill out next section:
Yes ☒ No ☐
Contact Name: 
National ID Number: 
Phone: 
Extension: 
Mobile: 

Invoice No. (Sadad): 

Version 3.2 - 15/12/2013
### Center Manager Commitment

In case of termination of my contract with the establishment/company for any reason I promise to inform SFDA within fifteen days start by last working day.

I have read all terms and conditions of the Drug Establishment Executive Guidelines issued by Royal decision No. M/31 dated 1/6/1425 Hj. (Published in SFDA web site) and I promise to follow all its content and any regulations followed. Also I promise to follow any regulation issued by SFDA in future.

**Manager Signature:**  
**Name:**  
**Date:**  
**Stamp:**

*Signature should be confirmed by Commercial Chamber*
Owner Commitment

This form has been filled by my knowledge with complete and correct information. Also, all attached documents are stamped by company's stamp and considered as an official copy. I take the extreme responsibility for any forgery or incorrect information on these documents.

I promise to update any changes in the current information.

I have read all terms and conditions of the Drug Establishment Executive Guidelines issued by Royal decision No. M31 dated 1/6/1425 Hj. (Published in SFDA web site) and I promise to follow all its content and any regulations followed. Also I promise to follow any regulation issued by SFDA in future.

Owner/ General Manager (for companies) signature: ____________________________

Name: ____________________________ Date: ____________________________

Stamp: ____________________________

Signature should be confirmed by Commercial Chamber
**المتطلبات المطلوبة للطلب أو تعديل معطيات مركز استيرادات موادية:***

<table>
<thead>
<tr>
<th>المتطلبات المطلوبة للطلب أو تعديل معطيات مركز استيرادات موادية</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. أن يتم تقديم طلب تجديد الترخيص قبل ستة أشهر من تاريخ انتهائه.</td>
</tr>
<tr>
<td>2. الحصول على رخصة الدفع المناسبة.</td>
</tr>
<tr>
<td>3. الحصول على رخصة البالغين.</td>
</tr>
<tr>
<td>4. تعتبر دليلاً للمركز أن يكون صادقاً ودليلاً ودقيقاً.</td>
</tr>
<tr>
<td>يجب أن يوفر نظام إدارة بيانات المركز معلومةً تفصيليةً لجميع البيانات والوثائق بحث بمراجعتها والمصادقة عليها واسترجاعها عند الحاجة.</td>
</tr>
<tr>
<td>يجب أن يكون المركز خاص.</td>
</tr>
</tbody>
</table>

**إرشادات مواصلات التفاصيل والتواصول الآسيوي:**

1. أن يتم عرض الفاتورة المحاسبية والإدارية والمقالة الإدارية عند الطلب منها. |
2. عدم إرسال أي أدلة أخرى إلا بعد الحصول على موافقة الهيئة. |
3. الإبلاغ بالوسائل السريعة لإجراء الإجراءات الرسمية. |
4. الإبلاغ بالأعداد الإدارية المقدمة للجهة المعنوية للدورة الرسمية (ICH). |
5. الإبلاغ بالأعداد الإدارية المقدمة للدورة الرسمية للمدفوعات. |
6. إن الأفضل هو أن تكون البيانات المقدمة للدورة الرسمية عن 180 متراً. |
7. إن يحوي الأقسام الفنية لدورة التدريب والتواصول الآسيوي على عربة مكلفة ما يلي:
   - عربة تسجيل المشاريع والتحاليل |
   - عربة رخصة المعرفة |
   - عربة الولايات المتحدة |
8. إن يكون المركز على مستوى عال. |
9. إن يكون مثيراً للصدارة في الخلايا والدولية للاستدامة في حالة طارئة، على أن تكون الأجهزة المطلوبة للاستدامة القبل والرئيسي. |
10. يتغير النتائج مع عدم المستندات المختلفة بتكوين أي حالة طارئة، على أن تكون الأجهزة المطلوبة للاستدامة القبل والرئيسي. |
11. إن يتوفر في المركز على مدى دورات تدريب إجراء الإجراءات التفاصيل والتواصول الآسيوي. |
12. إن يتم تخصيص مقر للدورة الإدارية والاجتماعية في الدورة الرسمية. |
13. إن تكون الدورة الإدارية والاجتماعية في الدورة الرسمية معتمدة. |
14. إن يتم اتخاذ إجراءات التدريب بطريقة تجدب من فرص القياس. |
15. إن تكون الردود المستمرة مقدمة في عربة خاصة بحيث لا تكون مثلاً إجراء أخرى. |
16. إن تكون الردود المستمرة من مواقف عبر قلباً لإشراف، ولا تتأثر بما يعود الهيكلية وسيلة التدريب. |
17. إن يكون مثيراً للصدارة في الخلايا الرسمية للدورة الرسمية، يشير إلى أن يكون رفعًا غير متناقضًا عن مثير تحليل المستندات الصيدلانية في المنازل. |
18. الإبلاغ بالوسائل السريعة لإجراء الإجراءات الرسمية للمدفوعات. |
19. التواصل مع شركة مختصة للتحول من النقياسات الجمالية والكمeselect.
### Maintenance of Marketing Authorizations in the MENA Region

<table>
<thead>
<tr>
<th>شروط شروط نشاطmant Raqasa الطيار وتورار الحيواني</th>
<th>قانونن ونسلع</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>أن تكون في المسألة عن تحليل التحليل البيولوجي (في حال وجودها) التحليل البيولوجي.</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>أن يكون نتيجة الخروج متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على أن تجربة في أحد تخصصات المختبر البيئية مع خبرة من تجربة في التحليل الكيميائي أو الكيماوي أو اختبار المحلة.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن تحليل المستحضرات الصيدلانية في المواد الحيوانية التحليل البيولوجي.</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو الكيماويات الكيميائية الصيدلانية. من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في مسابقة معترف بها من جهاز الاستخدام.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون صناعي أو كيميائي متغير ومرخص له.</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في مسابقة معترف بها من جهاز الاستخدام.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في مسابقة معترف بها من جهاز الاستخدام.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>شروط شروط تحليل المستحضرات الصيدلانية ومنتجات التحليل</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن تحليل المستحضرات الصيدلانية الشروط البيولوجية.</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو الكيماويات الصيدلانية من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن تكون في المسألة عن شروط النوعية الشروط البيولوجية.</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>أن يكون صناعي أو كيميائي متغير ومرخص له.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أن يكون حساساً على استخدام التحاليل الكيميائية أو ضبط المحلة من جامعة معترف بها.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>أو أن تكون خروج لا تقل عن خمس سنوات في التحليل الكيميائي أو الكيماوي أو اختبار المحلة أو منتجات البيولوجية.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version 3.2 - 15/12/2013

السدة 2013/12/15
## Maintenance of Marketing Authorizations in the MENA Region

### Saudi Food & Drug Authority

#### Shoura Regulations and Procedures

<table>
<thead>
<tr>
<th>Clause</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Must have the facilities and equipment necessary for manufacturing.</td>
</tr>
<tr>
<td>2</td>
<td>Must have a registered office and a registered person.</td>
</tr>
<tr>
<td>3</td>
<td>Must have a registered representative in the region.</td>
</tr>
<tr>
<td>4</td>
<td>Must have a registered representative in the region.</td>
</tr>
<tr>
<td>5</td>
<td>Must have a registered representative in the region.</td>
</tr>
</tbody>
</table>

### Conditions

<table>
<thead>
<tr>
<th>Clause</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>2</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>3</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>4</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>5</td>
<td>Failure to provide required information or documents.</td>
</tr>
</tbody>
</table>

### Amendments

<table>
<thead>
<tr>
<th>Clause</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>2</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>3</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>4</td>
<td>Failure to provide required information or documents.</td>
</tr>
<tr>
<td>5</td>
<td>Failure to provide required information or documents.</td>
</tr>
</tbody>
</table>

**Version 3.2 - 15/12/2013**

**السيرة الدقيقة 3.2 - 1435/12/12 هـ**
### Maintenance of Marketing Authorizations in the MENA Region

<table>
<thead>
<tr>
<th>Document Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saudi Food &amp; Drug Authority and Kingdom of Saudi Arabia</td>
</tr>
</tbody>
</table>

#### Required Documents:

1. **Authorization Certificate**
2. **Authorization Registration Certificate**
3. **Authorization Renewal Certificate**
4. **Authorization Transfer Certificate**
5. **Authorization Cancellation Certificate**
6. **Authorization Reissue Certificate**
7. **Authorization Amendment Certificate**
8. **Authorization Change Certificate**
9. **Authorization Extension Certificate**
10. **Authorization Reconfirmation Certificate**
11. **Authorization Non-Recurrence Certificate**
12. **Authorization Revocation Certificate**
13. **Authorization Revocation Reconfirmation Certificate**
14. **Authorization Revocation Reconfirmation Reconfirmation Certificate**
15. **Authorization Revocation Reconfirmation Reconfirmation Reconfirmation Certificate**

*All documents should be valid.*

---

**Note:**
- All documents required for the maintenance of marketing authorizations must be submitted to the Saudi Food & Drug Authority.
- Each document is essential for the proper administration of marketing authorizations in the MENA region.

---

**Version:** 3.2 - 15/12/2013

---

**السماحة:**
- **MENA Region**
- **Marketing Authorizations**
- **Saudi Food & Drug Authority**

---
Annex II - Application Form for Renewal of a conventional medicinal products UAE

DEclarations for renewal of registration of a conventional pharmaceutical product

- Read the accompanying notes carefully before completing this application, any incorrect information will delay the process of registration for the product.
- Declaration should be properly filled, signed and stamped and no handwriting or correction is accepted.
- The original certificate of principle product and (2) samples + Certificate of analysis should be submitted along with this declaration.
- A copy of CPP should be submitted along with this declaration.
- Two sets of outer pack, inner label and package insert with a soft copy in a labeled CD in a JPEG format should be submitted along with this declaration.
- Soft copy of renewal file should be submitted in a labeled CD
- This Form is for each product strength
- This Declaration should be submitted during 3 months before the registration of principle product expiry, otherwise the registration of the product will be cancelled
- A scanned copy of the Renewal Declaration [Section B] is accepted until the original declaration is ready for submission
- Fees should be paid before submission.

<table>
<thead>
<tr>
<th>For Official Use Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application No.</td>
</tr>
<tr>
<td>Received Date</td>
</tr>
<tr>
<td>Received By</td>
</tr>
</tbody>
</table>

Section A: Product Details

A.1 Details of Local Distributor

<table>
<thead>
<tr>
<th>Name</th>
<th>Store license</th>
<th>No. &amp; Expiry date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address</th>
<th>Postal Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tel</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A.2 Details of the Marketing Authorization Holder in COO

<table>
<thead>
<tr>
<th>Name of Marketing Authorization Holder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
## A.3 Details of product

<table>
<thead>
<tr>
<th>Name of Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Ingredient(s)</td>
</tr>
<tr>
<td>Dosage Form and Unit Strength</td>
</tr>
<tr>
<td>Registration Number in UAE</td>
</tr>
<tr>
<td>Date of first Registration in UAE</td>
</tr>
<tr>
<td>Date of last Registration in UAE</td>
</tr>
<tr>
<td>Registered Packs Size(s)</td>
</tr>
<tr>
<td>Describe the packaging of primary and/or secondary material and color of pack</td>
</tr>
<tr>
<td>Shelf Life at last registration</td>
</tr>
<tr>
<td>Storage Conditions</td>
</tr>
<tr>
<td>Registration Status in other countries since 5 years (List of countries)</td>
</tr>
<tr>
<td>Has the Product been subjected to any Minor Variation According to UAE MOH Guidelines? Yes □ No □</td>
</tr>
</tbody>
</table>

If yes please attach a copy of the Minor Variation Notification(s).
<table>
<thead>
<tr>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product has been on the UAE market during last 3 years?</td>
</tr>
<tr>
<td>Product has been banned or cancelled in the country of origin or any country the product marketed in it since last 5 years?</td>
</tr>
<tr>
<td>If, yes please give detail(s):</td>
</tr>
<tr>
<td>Product has been recalled in the country of origin or other countries where the product is marketed or from UAE market since last 3 years?</td>
</tr>
<tr>
<td>If yes, please provide the recall report within 6 months from the renewal declaration submission date:</td>
</tr>
<tr>
<td>Mode of dispensing at last registration:</td>
</tr>
<tr>
<td>Has there been any change in mode of dispensing in the last five years in the country of origin?</td>
</tr>
<tr>
<td>Has there been any change in mode of dispensing in the last five years in UAE?</td>
</tr>
<tr>
<td>If, yes please give detail(s):</td>
</tr>
<tr>
<td>Recommended dose</td>
</tr>
<tr>
<td>Therapeutic Classification(s) &amp; Clinical Indication(s) at last Registration</td>
</tr>
</tbody>
</table>
Have the Arabic/English leaflet been presented with the product during the last registration?

Yes ☐ No ☐

If No, please give detail(s)

Regarding the Pharmacovigilance programs, has there been a compliance Protocol for UAE market?

Yes ☐ No ☐

If Yes, please answer the following questions:

Do you conduct any Pharmacovigilance activities in UAE?

Yes ☐ No ☐

How often the PSUR report has been submitted to Registration and Drug Control Department?

Every 6 months ☐ Every 12 months ☐ Others. Specify (As per current UAE requirements) ☐

Has there been any unexpected or serious Adverse Event occurred?

Yes ☐ No ☐

If, yes please give detail(s)

Has there been any unexpected or serious Adverse Drug Reaction occurred?

Yes ☐ No ☐

If, yes please give detail(s)

Is the Product still under patent protection in COO?

Yes ☐ No ☐

If Yes, fill the following details:

<table>
<thead>
<tr>
<th>Description of patent</th>
<th>Patent Number</th>
<th>Term of validity / Expiry date</th>
<th>Patent Holder</th>
<th>Address of patent office issued / Country</th>
</tr>
</thead>
</table>

Page 4 of 13
### Qualified Authorized Person Details

<table>
<thead>
<tr>
<th>Qualified Authorized Person</th>
<th>Qualifications [Mention briefly]</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Please attach letter of attorney for the qualified authorized person from the company mentioning his/her qualifications and responsibilities.

### A.4 Declaration

- I hereby make application for the above product to be renewed.
- I declare that all of the information provided above is true & correct. If the information is incorrect, misrepresented I am willing to accept denial of permission or termination of this case.
- I declare to provide any documents required.
- I have a standard operating procedure for handling adverse reaction reports on its products.
- I have a standard operating procedure for handling batch recalls of this product.
- The product covered by this declaration will not be marketed, if any change in the ownership, address/location, manufacturer, therapeutic indication, packaging of the Principal product without Informing the Drug Control Department.
- We acknowledge and agree that in the event that there is an unauthorized change in the manufacturer, ingredients, pharmaceutical formulation, dosage form, strength, manufacturing process, labeling or commercial presentation and packaging of the Principal product, will be subjected to the following action.
  - Drug Control Department suspend the registration of product, and
  - I will voluntarily recall the product from the market.
- We agree that the manufacturing site mentioned in the declaration may be subjected to inspection any time decided by Drug Control Department to ensure the GMP compliance. The cost of Inspection shall be at our expense.
- Finally, we agree and bind ourselves that any material change in formulation, labeling, and technical specification in the product in the future will be duly communicated and cleared with the Drug Control Department.
- I hereby declare that I am aware of and comply with pharmacovigilance system on behalf of the company, and I will notify the Drug Control Department with any information related to safety, efficacy and quality of the product.
- I acknowledge and agree that if there is an unauthorized change in the above information will be subjected to the following action.
  A. Drug Control Department suspend the registration of product, and
  B. I will voluntarily recall the product from the market.
**Section B: Product Formulation Details**

### B.1 Qualified person responsible for batch release (in Manufacturing site)

<table>
<thead>
<tr>
<th>Qualified Person Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
<td></td>
</tr>
<tr>
<td>Postal Code</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>Country</td>
</tr>
<tr>
<td>Tel</td>
<td>Fax</td>
</tr>
<tr>
<td>E-mail</td>
<td>Mobile phone No.</td>
</tr>
</tbody>
</table>

### B.2 Manufacturing Site(s)
Manufacturer(s) of the medicinal product

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
<td></td>
</tr>
<tr>
<td>Postal Code</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>Country</td>
</tr>
<tr>
<td>Tel</td>
<td>Fax</td>
</tr>
<tr>
<td>Website address</td>
<td></td>
</tr>
<tr>
<td>Latest GMP Certificate Details + Expiry date</td>
<td></td>
</tr>
</tbody>
</table>

Has the manufacturing Site been registered in Drug Control Department in UAE?  
Yes [ ] No [ ]

If yes, please give the certificate No. and its expiry date:

**CERF No.:**

**EXP. Date:**
**Functions performed by the manufacturing site**

<table>
<thead>
<tr>
<th>Total manufacturer</th>
<th>Bulk Manufacturer</th>
<th>Packaging &amp; labelling</th>
<th>Batch releaser</th>
</tr>
</thead>
</table>

Give brief description:

If the Manufacturer is not the same as the applicant for renewal, indicate relationship:

- [ ] Contract Manufacturer
- [ ] Toll Manufacturer

For each manufacturing facility please refill part B.2

**B.2A For Blood products and Vaccines**

State laboratory or laboratory designated for official batch release

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Postal Code</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>Country</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Tel</th>
<th>Fax</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail</th>
<th>Mobile Phone No.</th>
</tr>
</thead>
</table>

Brief description of the functions performed.

**B.3 Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s)**

<table>
<thead>
<tr>
<th>Name of Active ingredient</th>
<th>Quantity/Unit Dose</th>
<th>Quality standard [Ph Eur / BP / USP / H.62]</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Name of Excipient(s)</th>
<th>Quantity/Unit Dose</th>
<th>Function</th>
<th>Quality standard [Ph Eur / BP / USP / H.62]</th>
</tr>
</thead>
</table>
B.4 Ingredients of Animal Origin

Ingredient(s) of animal origin contained or used in the manufacturing process of the medicinal product.

Animal origin susceptible to TSE

All batches of ingredients of animal origin are obtained from the following source(s):

<table>
<thead>
<tr>
<th>Name of the Supplier</th>
<th>Address of the Supplier</th>
</tr>
</thead>
</table>

The product contains no ingredients derived from animals. If applicable, is any stearate or stearic acid in the product derived from a vegetable source?

Yes [ ] No [ ]

Does the product contain (or come into contact during its manufacture) with animal-derived materials that are potential sources of TSE agents but appropriate precautions are taken in accordance with the European Commission and US Food and Drug Administration requirements to minimize the risk of contamination with TSE agents?

Yes [ ] No [ ]

NOTE: If a product contains an ingredient (active or excipient, e.g. magnesium or calcium stearate, stearic acid, lactose, gelatin) that is, or potentially is, of animal origin, or comes into contact with material of animal origin during manufacture, the source of the material (or contact) must be declared, and evidence must be provided that the product is free from viruses, other micro-organism transmissible spongiform encephalopathy (TSE) agents (e.g. a European Pharmacopoeia Commission C55) is acceptable as evidence of freedom from TSE agents.

B.5 Source of Active Ingredients

Name of Active Ingredient(s)
### Maintenance of Marketing Authorizations in the MENA Region

**UNITED ARAB EMIRATES**
**MINISTRY OF HEALTH & PREVENTION**

**NOTE:**
Only one name should be given in the following order of priority: INN*, European Pharmacopoeia, common name, scientific name. The active substance should be indicated by its recommended INN International non-proprietary name, accompanied by its salt or hydrate form (if any).

<table>
<thead>
<tr>
<th>Manufacturer of active ingredient</th>
<th>Only final manufacturer should be specified.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Address of site of Manufacture</th>
<th>Postal Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>Country</td>
</tr>
</tbody>
</table>

GMP certificate issued by

No. of Certificate / Date of Issue / Date of Expiry

Where an active ingredient manufacture has been inspected by reference country - name of competent authority which carried out the inspection, date of inspection & type of inspection (pre/post-authorization/special/re-inspection)

1

2

**For Generic Products:**
Has a Ph.Eur. Certificate of suitability been issued for the active substance(s), or obtained DMF approval by US FDA or from any reference Pharmacopoeial Organizations:

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

If yes please give detail (s) of approval:
Certificate of suitability (COS) No. Issue Date:

Or

Drug Master File (DMF) US No. Submission Date:

**For Innovators:**
Has the DMF submitted to UAE?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

Has the DMF been evaluated by any reference countries e.g. (TGA, MHRA, EMEA, Health...)

Page 10 of 13
CARE CANADA, AFSSAPS, US FDA or Japan Pharmacopeias?
If, yes please attach a copy of product registration certificate in this country.

### B.6 For Biological, Biotechnology, and Immunological Medicinal Product

- **Active Substance derived from human blood or plasma**
  - Name of Active Substance:

- Is each batch of finished product marketed in UAE subject to control authority batch release?
  - Yes ☐ No ☐

- Does all plasma pools used in the manufacture of the active substance(s) conform to specifications of any International Reference Pharmacopoeia on human plasma for fractionation and pooled and treated for virus inactivation?
  - Yes ☐ No ☐

- If, yes please give the reference Pharmacopoeias (e.g. Ph. Euro. Monograph)

- **Excipient(s) derived from human blood or plasma**
  - Name of Excipient(s):

- Is each batch of human blood- or plasma - derived Excipient subject to control authority batch release?
  - Yes ☐ No ☐

- Does all plasma pools used in the manufacture of this Excipient conform to specifications of any International Reference Pharmacopoeia on human plasma for fractionation and pooled and treated for virus inactivation?
  - Yes ☐ No ☐

- If, yes please give the reference Pharmacopoeias (e.g. Ph. Euro. Monograph)

- **Plasma Master File**
  - Has a current Plasma Master File (PMF) submitted to UAE drug control department and/or Other Drug Control Authority in other countries to be assessed as Plasma Master File
Maintenance of Marketing Authorizations in the MENA Region

Certification Procedure in respect of the plasma used to manufacture each blood or plasma-derived substance which is a component of the finished product?

Yes ☐ No ☐

If yes please list the Name of Drug Control authority/countries where the PMF has been assessed?

1. 
2. 
3. 

If No, is a PMF attached to this application to be assessed by Drug Control Laboratory?

Yes ☐ No ☐

☐ Virus Inactivation procedures

Do the virus inactivation procedures carried out on the manufacturing processes for this product comply with requirements?

Yes ☐ No ☐

If yes, please justify (check the appropriate)


☐ Immunological Medicinal Products

Name of active substance(s)

Is each batch of finished product marketed in UAE subject to control authority batch release?

Yes ☐ No ☐
**B.7 Declaration**

We categorically declare that all data and information submitted with this application as well as other submission in the future are true and correct and reflect the total information required. We certify that we have examined the following statements and we attest to their accuracy that:

1. The Current Good Manufacturing Practice Guidelines for Drugs is applied in full in the manufacture of this product.
2. The formulation per dosage form is in agreement with the master formula and with the batch manufacturing record forms.
3. The manufacturing procedure is exactly as specified in the master formula and batch manufacturing records.
4. Each batch of all starting materials is tested or certified (in an accompanying certificate of analysis for that batch) against the full specifications and fully complied with those specifications cited in the claimed reference official monograph before it is released for manufacturing purposes.
5. All batches of active pharmaceutical ingredient(s) (API) are obtained from the same source mentioned in this application.
6. No batch of active pharmaceutical ingredient will be used unless a copy of the batch certificate established by the active ingredient manufacturer is available.
7. Each batch of the finished product is tested and certified (in an accompanying certificate of analysis for that batch), against the full specifications and fully complied with the specifications cited in the claimed reference official monograph before it is released for sale.
8. The person releasing the product for sale is an authorized and/or qualified person.
9. The procedures for control of the finished product have been validated for this formulation. The assay method has been validated for accuracy, precision, specificity, and linearity.
10. We declare that the product does not contain ingredients and additives that are not permitted for use in human or animal in accordance with international references regulations and its free from derivatives of pork meat and any natural and chemical ingredients having harmful effects on human biological and behavioral functions.
11. We agree that the product may be subjected to analysis at drug control laboratory any time to verify the product’s safety, quality and conformity with labeling claims.

<table>
<thead>
<tr>
<th>Name of Batch releaser (site) :</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Qualified person responsible for batch release:</td>
</tr>
<tr>
<td>Signature:</td>
</tr>
<tr>
<td>Stamp:</td>
</tr>
</tbody>
</table>
### Annex III - Renewal Application Form for General sale - UAE

#### DRUG DEPARTMENT

#### DECLARATIONS FOR RENEWAL / RE-REGISTRATION OF A GENERAL SALE LIST PRODUCT

- Read the accompanying notes carefully before completing this application, any incorrect information will delay the process of registration for the product.

<table>
<thead>
<tr>
<th>For Official Use Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application No.:</td>
</tr>
<tr>
<td>Type of product</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Received Date</td>
</tr>
<tr>
<td>Received By</td>
</tr>
</tbody>
</table>

#### 1 Detail of Local Distributor

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
</tr>
<tr>
<td>Postal Address</td>
</tr>
<tr>
<td>Tel:</td>
</tr>
<tr>
<td>Email:</td>
</tr>
</tbody>
</table>

#### 2 Detail of the Applicant

<table>
<thead>
<tr>
<th>Name of Marketing Authorization Holder in COO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address/Street</td>
</tr>
<tr>
<td>City</td>
</tr>
<tr>
<td>Country</td>
</tr>
<tr>
<td>Website:</td>
</tr>
<tr>
<td>Qualify person</td>
</tr>
<tr>
<td>Qualification: mention briefly</td>
</tr>
<tr>
<td>City:</td>
</tr>
<tr>
<td>DRUG DEPARTMENT</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Tel/Fax</td>
</tr>
<tr>
<td>International Code:</td>
</tr>
<tr>
<td>Email:</td>
</tr>
</tbody>
</table>

I hereby declare that I am aware of and comply with pharmacovigilance system on behalf of the company, and I will notify the Drug Control Department with any information related to safety, efficacy and quality of the product.

Name of Applicant:

Name of the Qualify person:

Signature:

Stamp:

### 3 Detail of product

<table>
<thead>
<tr>
<th>Name of Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
</tr>
<tr>
<td>Dosage Form and Unit Strength</td>
</tr>
<tr>
<td>Registration Number</td>
</tr>
<tr>
<td>Date of last Registration</td>
</tr>
<tr>
<td>Registered Packs Size</td>
</tr>
<tr>
<td>Physical Appearance</td>
</tr>
<tr>
<td>Primary Packaging (Market or Commercial Presentation)</td>
</tr>
<tr>
<td>Shelf Life at last registration</td>
</tr>
<tr>
<td>Storage Conditions</td>
</tr>
</tbody>
</table>

Page 2 of 9
<table>
<thead>
<tr>
<th>Registration Status in other countries since 5 years (List of countries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
</tr>
<tr>
<td>-</td>
</tr>
<tr>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product has been on the UAE market during last 3 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes [ ] No [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product has been revoked/ banned in the country of origin or any country product marketed</th>
</tr>
</thead>
<tbody>
<tr>
<td>If, yes please give detail (s):</td>
</tr>
<tr>
<td>Yes [ ] No [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product has been recalled in the country of origin or any country product marketed or from UAE market since registration?</th>
</tr>
</thead>
<tbody>
<tr>
<td>If, yes please give detail (s):</td>
</tr>
<tr>
<td>Yes [ ] No [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of dispensing at last registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>POM [ ] P [ ] GS (S) [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Has there been any change in mode of dispensing in the last five years in the country of origin?</th>
</tr>
</thead>
<tbody>
<tr>
<td>If, yes please give detail (s):</td>
</tr>
<tr>
<td>Yes [ ] No [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Has there been any change in mode of dispensing in the last five years?</th>
</tr>
</thead>
<tbody>
<tr>
<td>If, yes please give detail (s):</td>
</tr>
<tr>
<td>Yes [ ] No [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommended dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single: Average: Maximum:</td>
</tr>
<tr>
<td>Daily: Average: Maximum:</td>
</tr>
</tbody>
</table>
**3. Manufacturing Site**

Manufacturer(s) of the medicinal product

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
<td></td>
</tr>
<tr>
<td>Postal Code</td>
<td></td>
</tr>
</tbody>
</table>

Page 4 of 9
DRUG DEPARTMENT

<table>
<thead>
<tr>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tel</td>
<td>Fax</td>
</tr>
</tbody>
</table>

Name & Date of Latest GMP certification issued:

Has the manufacturing Site been registered in Drug Control Department
- Yes [ ]
- No [ ]

If yes please give the certificate No. and its expiry date:

CERF No.: [ ]

EXP. Date: [ ]

Functions performed by the manufacturing site
- Total manufacturer [ ]
- Bulk Manufacturer [ ]
- Packaging & labeling [ ]
- Batch release [ ]

Give brief description:

If the Manufacturer is not the same as the applicant for renewal/re-registration, indicate relationship
- Contract Manufacturer [ ]
- Toll Manufacturer [ ]

If the above manufacturer is not the Batch releaser, please fill the below Information

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Postal Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>Country</td>
<td>Fax</td>
</tr>
</tbody>
</table>

Name & Date of Latest GMP certification issued:
### 6. Ingredients of Animal Origin

*Ingredients of animal origin contained or used in the manufacturing process of the medicinal product*

<table>
<thead>
<tr>
<th>Animal origin susceptible to TSE</th>
<th>Other animal origin</th>
</tr>
</thead>
</table>

*All batches of Ingredients of animal origin are obtained from the following source(s):*

<table>
<thead>
<tr>
<th>Name and Address of Manufacturer</th>
<th>Name and Address of Supplier</th>
</tr>
</thead>
</table>

**TSE Declaration By Quality Assurance In charge**

*The product contains no ingredients derived from animals. If applicable, is any stearate or stearic acid in the product derived from a vegetable source?*

*Signature & Stamp*
The product contains (or comes into contact during its manufacture) with animal-derived materials that are potential sources of TSE agents but appropriate precautions are taken in accordance with the European Commission and US Food and Drug Administration requirements to minimize the risk of contamination with TSE agents.

7. Declaration

We categorically declare that all data and information submitted with this application as well as other submission in the future are true and correct and reflect the total information required. We certify that we have examined the following statements and we attest to their accuracy that:

- I hereby make application for the above product to be renewed.
- I declare that all of the information provided above is true & correct. If the information is incorrect, misrepresented I am willing to accept denial of permission or termination of this case.
- I declare to provide any documents required.
- I have a standard operating procedure for handling adverse reaction reports on its products.
- I have a standard operating procedure for handling batch recalls of this product.
- The product covered by this declaration will not be marketed, if any change in the ownership, address/location, manufacturer, therapeutic indication, packaging of the Principal product without Informing the Drug Control Department.
- I acknowledge and agree that if there is an unauthorized change in the above information will be subjected to the following action.
- Drug Control Department suspend the registration of product, and I will voluntarily recall the product from the market.
- The Current Good Manufacturing Practice Guidelines for Drugs is applied in full in the manufacture of this product.
- The formulation per dosage form is in agreement with the master formula and with the batch manufacturing record forms.
- The manufacturing procedure is exactly as specified in the master formula and batch manufacturing records.

Each batch of all starting materials is tested or certified (in an accompanying
DRUG DEPARTMENT

Certificate of analysis for that batch) against the full specifications and fully complied with those specifications cited in the claimed reference official monograph before it is released for manufacturing purposes.

Each batch of the finished product is tested and certified (in an accompanying certificate of analysis for that batch), against the full specifications and fully complied with the specifications cited in the claimed reference official monograph before it is released for sale.

The person releasing the product for sale is an authorized and/or qualified person.

The procedures for control of the finished product have been validated for this formulation. The assay method has been validated for accuracy, precision, specificity, and linearity.

We acknowledge and agree that in the event that there is an unauthorized change in the manufacturer, ingredients, pharmaceutical formulation, dosage form, strength, manufacturing process, labeling or commercial presentation and packaging of the Principal product, will be subjected to the following action.

Drug Control Department suspend the registration of product, and

I will voluntarily recall the product from the market.

We declare that the product do not contain ingredients and additives that are not permitted for use in human/or animal in accordance with international regulations and its free from derivatives of pork meat and any natural and chemical ingredients having harmful effects on human biological and behavioral functions.

We agree that the product may be subjected to analysis at drug control laboratory any time to verify the product’s safety, quality and conformity with labeling claims.

We agree that the manufacturing site mentioned in the declaration may be subjected to inspection any time decided by Drug Control Department to ensure the GMP compliance. The cost of inspection shall be at our expense.

Finally, we agree and bind ourselves that any material change in formulation, labeling, and technical specification in the product in the future will be duly communicated and cleared with the Drug Control Department.

Name of Applicant:

Name of Registrant Officer:

Signature & Stamp
Maintenance of Marketing Authorizations in the MENA Region

Annex IV - Application form for Renewal for Herbal Medicinal Product - UAE

DECLARATIONS FOR RENEWAL / RE-REGISTRATION OF A HERBAL PRODUCT

- Read the accompanying notes carefully before completing this application, any incorrect information will delay the process of registration for the product.

<table>
<thead>
<tr>
<th>For Official Use Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application No.:</td>
</tr>
<tr>
<td>Type of product</td>
</tr>
<tr>
<td>- Dietary supplement</td>
</tr>
<tr>
<td>- Medicated Cosmetic</td>
</tr>
<tr>
<td>- Antiseptic and Disinfectant</td>
</tr>
<tr>
<td>- Miscellaneous</td>
</tr>
<tr>
<td>Received Date</td>
</tr>
<tr>
<td>Received By</td>
</tr>
</tbody>
</table>

1 Detail of Local Distributor

- Name
- Address
- Postal Address
- Tel:       Fax:
- Email:

2 Detail of the Applicant
(Marketing Authorization Holder in COO)

- Name of Marketing Authorization Holder in COO
- Address/Street
- City
- Country
- Website:
- Qualify person
- Qualification: mention briefly
- City:       Country:
I hereby declare that I am aware of and comply with pharmacovigilance system on behalf of the company, and I will notify the Drug Control Department with any information related to safety, efficacy and quality of the product.

Name of Applicant:

Name of the Qualify person:

Signature:

Stamp:

### 3 Detail of product

<table>
<thead>
<tr>
<th>Name of Product</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td></td>
</tr>
<tr>
<td>Dosage Form and Unit Strength</td>
<td></td>
</tr>
<tr>
<td>Registration Number</td>
<td></td>
</tr>
<tr>
<td>Date of last Registration</td>
<td></td>
</tr>
<tr>
<td>Registered Packs Size</td>
<td></td>
</tr>
<tr>
<td>Physical Appearance</td>
<td></td>
</tr>
<tr>
<td>Primary Packaging (Market or Commercial Presentation)</td>
<td></td>
</tr>
<tr>
<td>Shelf Life at last registration</td>
<td></td>
</tr>
<tr>
<td>Storage Conditions</td>
<td></td>
</tr>
</tbody>
</table>
### Drug Department

**Registration Status in other countries since 5 years (List of countries)**

**Product has been on the UAE market during last 3 years**

- Yes [ ]
- No [ ]

**Product has been revoked/banned in the country of origin or any country product marketed**

- Yes [ ]
- No [ ]

If yes, please give detail (s):

**Product has been recalled in the country of origin or any country product marketed or from UAE market since registration?**

- Yes [ ]
- No [ ]

If yes, please give detail (s):

**Mode of dispensing at last registration**

- POM [ ]
- P [ ]
- GS(S) [ ]

**Has there been any change in mode of dispensing in the last five years in the country of origin?**

- Yes [ ]
- No [ ]

If yes, please give detail (s):

**Has there been any change in mode of dispensing in the last five years?**

- Yes [ ]
- No [ ]

If yes, please give detail (s):

**Recommended dose**

- Single: Average [ ] Maximum [ ]
- Daily: Average [ ] Maximum [ ]
Maintenance of Marketing Authorizations in the MENA Region

DRUG DEPARTMENT

Therapeutic Classification(s) & Clinical Indication(s)
At last Registration

Have there been any change in therapeutic(s) classification and clinical indications in the last five years
Yes ☐ No ☐

If yes please give detail(s):

Are there significant differences in the following parts of the SPC: method of administration, Pharmacokinetics, contraindications, special warnings and precautions
Yes ☐ No ☐ Not Applicable ☐

If Yes, Has an application for variation to harmonize the SPCs been submitted?
Yes ☐ No ☐ Not Applicable ☐

If Yes, Please provide the Minor variation certificate of pharmaceutical product

Have the Arabic/English leaflet been presented with the product during the last registration
Yes ☐ No ☐ Not Applicable ☐

If No, please give detail(s)

4. Manufacturing Site
Manufacturer(s) of the medicinal product

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Postal Code</th>
</tr>
</thead>
</table>

Page 4 of 9
### Drug Department

<table>
<thead>
<tr>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tel</td>
<td>Fax</td>
</tr>
</tbody>
</table>

Name & Date of Latest GMP certification issued:

Has the manufacturing Site been registered in Drug Control Department?
- [ ] Yes
- [ ] No
- [ ] No

If Yes, please provide the certificate No. and its expiry date:

**CERT No.**

EXP. Date:

Functions performed by the manufacturing site:
- [ ] Total Manufacturer
- [ ] Bulk Manufacturer
- [ ] Packaging & Labeling
- [ ] Batch Released

Give brief description:

If the manufacturer is not the same as the applicant for renewal/re-registration, indicate relationship:
- [ ] Contract Manufacturer
- [ ] Toll Manufacturer

If the above manufacturer is not the Batch releaser, please fill the below information:

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
</tr>
<tr>
<td>Postal Code</td>
</tr>
<tr>
<td>City</td>
</tr>
<tr>
<td>Tel</td>
</tr>
</tbody>
</table>

Name & Date of Latest GMP certification issued:

Page 5 of 9
Brief description of the functions performed by the manufacturer

Has the batch releaser been registered in Drug Control Department
Yes [ ] No [ ]
If yes, please give the certificate No. and its expiry date:

CERF No.: [ ] EXP. Date: [ ]

Has the manufacturing procedures been changed since last registration
Yes [ ] No [ ]
If yes, please give detail(s):

Has the packaging and/or labelling of outer pack and/or inner pack been changed since last registration
Yes [ ] No [ ]
If yes, please give detail(s):

5. Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s)

<table>
<thead>
<tr>
<th>Name of Active ingredient</th>
<th>Quantity/Unit</th>
<th>Quality standard [Ph Eur / BP / US / House]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of Excipient(s)</th>
<th>Quantity/Unit</th>
<th>Function</th>
<th>Quality standard [Ph Eur / BP / US / House]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Maintenance of Marketing Authorizations in the MENA Region

#### 6. Ingredients of Animal Origin

**Ingredients of animal origin contained or used in the manufacturing process of the medicinal product**

<table>
<thead>
<tr>
<th>Animal origin susceptible to TSE</th>
<th>Other animal origin</th>
</tr>
</thead>
</table>

**All batches of ingredients of animal origin are obtained from the following source(s):**

<table>
<thead>
<tr>
<th>Name and Address of Manufacturer</th>
<th>Name and Address of Supplier</th>
</tr>
</thead>
</table>

**TSE Declaration By Quality Assurance In charge**

*The product contains no ingredients derived from animals. If applicable, is any stearate or stearic acid in the product derived from a vegetable source?*

*(Signature & Stamp)*

---

Page 7 of 9

110
7. Declaration

We categorically declare that all data and information submitted with this application as well as other submission in the future are true and correct and reflect the total information required. We certify that we have examined the following statements and we attest to their accuracy that:

- I hereby make application for the above product to be renewed.
- I declare that all of the information provided above is true & correct. If the information is incorrect, misrepresented I am willing to accept denial of permission or termination of this case.
- I declare to provide any documents required.
- I have a standard operating procedure for handling adverse reaction reports on its products.
- I have a standard operating procedure for handling batch recalls of this product.
- The product covered by this declaration will not be marketed, if any change in the ownership, address, location, manufacturer, therapeutic indication, packaging of the Principal product without Informing the Drug Control Department.
- I acknowledge and agree that if there is an unauthorized change in the above information will be subjected to the following action.
- Drug Control Department suspend the registration of product, and I will voluntarily recall the product from the market.
- The Current Good Manufacturing Practice Guidelines for Drugs is applied in full in the manufacture of this product.
- The formulation per dosage form is in agreement with the master formula and with the batch manufacturing record forms.
- The manufacturing procedure is exactly as specified in the master formula and batch manufacturing records.
- Each batch of all starting materials is tested or certified (in an accompanying certificate of analysis for that batch) against the full specifications and fully
DRUG DEPARTMENT

complied with those specifications cited in the claimed reference official monograph before it is released for manufacturing purposes.

Each batch of the finished product is tested and certified (in an accompanying certificate of analysis for that batch), against the full specifications and fully complied with the specifications cited in the claimed reference official monograph before it is released for sale.

The person releasing the product for sale is an authorized and/or qualified person.

- The procedures for control of the finished product have been validated for this formulation. The assay method has been validated for accuracy, precision, specificity, and linearity.

- We acknowledge and agree that in the event that there is an unauthorized change in the manufacturer, ingredients, pharmaceutical formulation, dosage form, strength, manufacturing process, labeling or commercial presentation and packaging of the Principal product, will be subjected to the following action.

- Drug Control Department suspend the registration of product, and

- I will voluntarily recall the product from the market.

- We declare that the product do not contain ingredients and additives that are not permitted for use in human/animal in accordance with international references; regulations and its free from derivatives of pork meat and any natural and chemical ingredients having harmful effects on human biological and behavioral functions.

- We agree that the product may be subjected to analysis at drug control laboratory any time to verify the products' safety, quality and conformity with labeling claims.

- We agree that the manufacturing site mentioned in the declaration may be subjected to inspection any time decided by Drug Control Department to ensure the GMP compliance. The cost of inspection shall be at our expense.

- Finally, we agree and bind ourselves; that any material change in formulation, labeling, and technical specification in the product in the future will be duly communicated and cleared with the Drug Control Department.

Name of Applicant:

Name of Registrant Officer:

Signature & Stamp
## Annex V - Renewal Application Form – Bahrain

### Medicine Renewal Application Form

<table>
<thead>
<tr>
<th>Product name</th>
<th>Strength</th>
<th>Form</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active substance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAH name</td>
<td>Registration number</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invoicing company name and address</td>
<td>ATC code</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **First Renewal** Yes [ ] No [x] Specify the date of last renewal: [ ]
- Shelf life: [ ]
- Storage conditions: [ ]
- Primary packaging: [ ]
- Method of sale: [ ]
- Leaflet revision date: [ ]
- Name of Manufacturer responsible for batch release: [ ]
- Name of API manufacturers: [ ]

Has the product market authorization withdrawn during last 5 years from any country where it was marketed?
- Yes [ ] No [x]
- If yes, please clarify: [ ]

---

I/we apply for a medicine license Renewal in respect of the product for which details are provided above. It is hereby confirmed that all information relevant to the product have been supplied in the file as appropriate and they are all correct (must be filled by the MAH).

- **Name of signatory**: [ ]
- **Signature**: [ ]
- **State capacity in which signed**: [ ]
- **Date**: [ ]

---

PPR0036 Jan 2016 Ver. 2 1
### Medicine Renewal Checklist

<table>
<thead>
<tr>
<th>Application number</th>
<th>Application date</th>
<th>Product name</th>
<th>Strength</th>
<th>Form</th>
<th>Pack Size</th>
<th>Active substance</th>
<th>MAH name</th>
<th>Local agent</th>
</tr>
</thead>
</table>

**First Renewal** Yes [ ] No [ ] Specify date of last renewal: [ ]

**Module 1**

1. Cover letter (original, company paper signed and dated).
2. eCTD validation report.
3. Copy of product licence.
4. List of variations approved and/or submitted since time of initial registration.
5. Legalised CPP (in WHO format) from the CDD (batch releaser).
6. Copy of valid manufacturer registration certificate in Bahrain (batch releaser).
7. Price certificate.
8. eCTD (Modules 1 and 3).
9. Laboratory file on a CD.

I declare that all the documents which refer to in this check list are attached.

**Date:**

**Name & Signature of responsible person:**

**Signature:**

---

**For internal use only**

I declare that I have received the documents as outlined in the above checklist.

**Name:**

**Date:**

**Signature:**

**Comments:**
APPLICATION FORM FOR HEALTH PRODUCT

This application form to be filled by the applicant by typing ONLY (original & one photocopy).

All the documents submitted with this application should either be in English or Arabic.

Arrangement of the documents in the folder should follow the same sequence followed in this form.

The documents required, as per Attachment II & III referring to requirements 8 & 9 respectively should be submitted in a separate folder.

Type of application: New ☐ Re-registration ☐

PART I: (To be filled by local agent)

1. Name & address of the Local Agent:

<table>
<thead>
<tr>
<th>Address</th>
<th>Administration Office</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.Box</td>
<td></td>
</tr>
<tr>
<td>P. C.</td>
<td></td>
</tr>
<tr>
<td>Tel. No.</td>
<td></td>
</tr>
<tr>
<td>Fax No.</td>
<td></td>
</tr>
<tr>
<td>E-Mail</td>
<td></td>
</tr>
</tbody>
</table>

2. Full description of the product: (Trade name, Strength & Pack size)

3. Name of the manufacturer:

4. Name of marketing authorization holder

5. Regn No. & date, if the manufacturer is registered with MOH Oman:

Name & Signature of the authorized pharmacist in the pharmacy

Stamp of the pharmacy
### REQUIREMENT OF DOCUMENTS

<table>
<thead>
<tr>
<th></th>
<th>MANUFACTURER</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Legalized cGMP Certificate of the manufacturer</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1.2</td>
<td>List of affiliated branches &amp; related manufacturers with address</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1.3</td>
<td>List of countries in which the company is registered</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1.4</td>
<td>List of the products manufactured by the Company</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1.5</td>
<td>If the marketing authorization holder is different from the manufacturer(s),</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(A) Legalized cGMP Certificate of the marketing authorization holder</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td></td>
<td>(B) A certificate showing the relation between the two companies (marketing</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td></td>
<td>authorization holder &amp; manufacturers)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### INFORMATION ABOUT THE PRODUCT

2.1 Trade Name of the product: __________________________________________

2.2 International Non proprietary name (INN): __________________________

2.3 Dosage Form: ______________________________________________________

2.4 Strength: _________________________________________________________

2.5 Pack size (By weight, volume or number of doses): ____________________

2.6 Type of packaging material: _________________________________________

2.7 Shelf life: _________________________________________________________

2.8 Storage Conditions in figures: ______________________________________
3. Legalized Certificate of Pharmaceutical Product (C.P.P) (WHO Certification Scheme or similar) or Free Sale Certificate

4. Scientific report containing:
   - Composition formula (Active & Inactive ingredients)
   - Pharmacological effects / mode of action
   - Therapeutic category
   - Indications
   - Dosage regimen & route of administration.
   - Precautions, warnings & contra-indications
   - Adverse Effects
   - Drug interactions
   - Incompatibilities
   - Use time period (shelf life after opening) - when applicable
   - Over dosage (briefly state symptoms, non-drug treatment, supportive therapy & specific anti-dote - if available)
   - Advantage claimed over similar other product if any 
   - Legal category in the country of origin.
   - List of References & Publications.

5. Pack insert (if available) legalized by the health authorities in the country of origin and 2 specimens of the pack insert are required.

6. Certificate issued from Company and legalized by authorities in country of origin showing that the products do not contain hormones, heavy metals, antibiotics, steroidal products, pork derivatives or any other natural or chemical materials which affect the behaviour and bio-functions of human (and if the product contains ingredients of animal origin, type of animal to be stated and the part from which material is taken and alcohol percentage should be stated with reasons for its use. alcohol content should be in following ranges:
   - 0.5% for children below 6 years
   - 5% children between 6 and 12 years
   - 10% above 12 years

3 - 4
7. Stability studies (if requested),

8. Ten samples & analysis requirements as per Annexure 10 of Circular No. 64/05

9. Two specimens of inner, outer packs & labels
   The outer packs and/or inner labels should contain the following:
   - Composition of the product
   - Warnings and precautions
   - Storage conditions in degree centigrade

10. List of countries where the product is registered & marketed supported by photocopies of registration certificates...
    if available

---

Name & Signature of the authorized pharmacist in the company

Stamp of the company

---

FOR OFFICIAL USE ONLY

Received  [ ] Not received  [ ]

Checked by (Reg.): ___________________  Checked by (QCL): ___________________

Signature: ___________________________  Signature: _________________________

Date: _______________________________  Date: ______________________________

Record No: ___________________  Date: __________________________

4 - 4
Annex VIII - Renewal Checklist – Kuwait

<table>
<thead>
<tr>
<th>Pharmaceutical Product Renewal checklist:</th>
<th>Submitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name/Dosage form/strength:</td>
<td></td>
</tr>
<tr>
<td>Registration Certificate of the product.</td>
<td></td>
</tr>
<tr>
<td>Variation approvals since registration.</td>
<td></td>
</tr>
<tr>
<td>Last renewal certificate (if applicable).</td>
<td></td>
</tr>
<tr>
<td>Manufacturer(s) registration certificate (Primary, secondary and batch releaser).</td>
<td></td>
</tr>
<tr>
<td>Product Sample (with COA) and leaflet, OR outer pack, label and leaflet mock-ups.</td>
<td></td>
</tr>
<tr>
<td>Original and legalized CPP:-</td>
<td></td>
</tr>
<tr>
<td>- Name of MAH:</td>
<td></td>
</tr>
<tr>
<td>- Name of manufacturer(s):</td>
<td></td>
</tr>
<tr>
<td>Container Closure system:</td>
<td></td>
</tr>
<tr>
<td>Pack size(s):</td>
<td></td>
</tr>
<tr>
<td>API supplier verification:</td>
<td></td>
</tr>
<tr>
<td>□ Letter form the principal company confirming API supplier(s) for the product.</td>
<td></td>
</tr>
<tr>
<td>GMP certificate:</td>
<td></td>
</tr>
<tr>
<td>Name of API manufacturer(s) and address:-</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
</tr>
</tbody>
</table>
Maintenance of Marketing Authorizations in the MENA Region

State of Kuwait
Ministry of Health
Drug and Food Control

- Stability study:-
  - Shelf life and duration submitted:
  - No. of batches and batch number:
  - Manufacturer:

☐ State otherwise, if not submitted:

______________________________
Agent's Signature:

Date: ____________________________

Stamp: ____________________________

Finished product specifications and detailed method of analysis (3.S.P.5.1 & 2) as a soft copy (CD) or a recent submission of specifications update file.
NEW HUMAN MEDICINE PRODUCT

REQUEST INQUIRY FORM

- Please note that, the company profile should be submitted in advance of the submission of the request inquiry form, in order to proceed with your application.
- You should submit a scanned copy of the receipt attached with the form (1000 L.E.), the company should specify the generic name, and strength and dosage form inside the receipt.
- Each form should be submitted for every individual product.
- The fee is UN refundable and applicable only for this product.
- All the items should be fulfilled completely.
- The company will receive a notification mail within 15 working days; if the box is closed and an action Letter if the box is opened.
- The reply email or the action letter will state the decline of the request and the decline of the request and the inquiry will be stored according to the receiving time.
- For more information: rdhd@eda.mohealth.gov.eg

Abbreviations:

- **FToll**: Manufacturing agreement between two manufacturing companies.
- **COO**: Country of origin
### Section 1: Application Type.

1.1 Type of registration:
- [ ] Local
- [ ] F Toll
- [ ] Toll
- [ ] Imported
- [ ] Under license
- [ ] Imported Bulk
- [ ] Toll / Under License

1.2 This Application Concern:
- [ ] Innovator Product
- [ ] Generic Products
- [ ] Line Extension

### Section 2: Applicant Company Information:

2.1. Applicant Company Name: 

2.2. Contact Email: 

### Section 3: Product Information.

3.1. Active ingredient(s) & strength(s): 

3.2. Dosage form: 

3.3. Route of administration: 

3.4. Pharmacotherapeutic group:
- [e.g. Antibacterial, Diuretic, etc.] 

3.5. Dose: 

3.6. Indication: 

3.7. Reference: 

3.8. Pack: 

122
### Section 4: Manufacturer Information:

| 4.1. Manufacturer Name: |

### Section 5: Additional information (For Imported & Under License Products)

| 5.1. Date of issue & expiration of CPP: |
| 5.2. Marketing Authorization Holder: |
| 5.3. Manufacturing site of the finished product: |
| 5.4. Manufacturer of accessories (if present): |
| 5.5. Packager: |
| 5.6. Batch Release: |

### Section 6: Declaration.

5.1. Applicant declaration

In accordance with the ministerial decree 296/2009. I certify that the information supplied is complete and correct and that no relevant information has been omitted.

* Name head of regulatory affairs manager:

* Date:

* Contact mobile No.
Annex X - Renewal Checklist – Iraq

1. Request for registration (original copy).
2. A letter from manufacturer declaring that there is no change(s) made on formula, manufacturing process & the specification (signed & stamped by the manufacturer).
4. Formula of the pharmaceutical product (signed & stamped by manufacturer).
7. Method of analysis in detail (stamped by the manufacturer for all pages).
9. Two valid samples.
10. Price certificate Ex-Factory, CIF price in Iraq & neighboring countries (original copy).
11. Compact disk (CD) of complete registration file includes common technical documents, stability study & bioequivalence study (if required). The CD should be labeled with the name of product & manufacturer (stamped by manufacturer).
12. Certificate of gelatin confirm that it is free from BSE & it is halal legalized from MOH in the country of the origin of gelatin.
<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.</td>
<td>Manufacturing method of the finished product (signed &amp; stamped by manufacturer)</td>
</tr>
<tr>
<td>15.</td>
<td>Copy of certificate of suitability (COS) for active ingredients' that found in the formula of the product or GMP certificate signed stamped by the manufacturer company of the product except brand company.</td>
</tr>
<tr>
<td>16.</td>
<td>In process specification signed by company itself.</td>
</tr>
<tr>
<td>17.</td>
<td>Letter from company refer that the product free from diethylene glycol if the formula contain propylene glycol signed and stamped by company itself.</td>
</tr>
<tr>
<td>18.</td>
<td>Certificate of pharmaceutical product (CPP) from the drug regulatory of country of origin (original copy)</td>
</tr>
</tbody>
</table>

**Signature:**

**Cod. No.:** (registration pharmacist)

**Name:**

**E-mail:**

**Mobile or Tel. No.:** (authorized representative person)
Annex XI – Application Form for renewal of chemical entities - Israel

Appendix 5

Checklist for submission of applications to the Chemical Products Unit
Registration renewal
EX-005R/02

CTD Module 1 - For all applications for the first renewal

- Application for the quality certificate in two copies.
- Appendix to the quality certificate in two copies.
- Original receipt
- Appendix 6 (Parts A and B)
- CPP
- Valid GMP approval for all manufacturing sites for the medicinal product (for the final medicinal product, solvent and sterile active ingredients only)
- QP statement for the supplier of the active ingredient\(^1\)
- Valid TSE declaration
- Analysis certificate for the active ingredient (for each supplier of the last five years) and the final medicinal product
- MSDS for all active ingredients
- Patient leaflet and physician leaflet
- Response to previous obligations
- List of recalls and reports of quality deficiencies of the medicinal product since the most recent renewal as well as reasons for these.
- List of variations that were approved since the most recent renewal (Appendix 1 of the variations guideline\(^2\)).

\(^1\) According to the guideline regarding the QP declaration, EX-314
\(^2\) According to Guideline EX-005/01 "Submission of applications for a quality certificate for the renewal of the registration of a medicinal product" (may be downloaded from the website [http://www.health.gov.il](http://www.health.gov.il))
The Institute of Standardization and Control of Pharmaceuticals | Guideline for submission of applications for renewal of a quality certificate for a medicinal product

| Guideline No EX-005/02 | Page 18 of 19 |

- Summary of the validation status and information about the medicinal product (Appendix 2 of the renewal guideline²)
- Only Variations of type IA, which were submitted together with the renewal according to the checklist for variations.

**Quality File**

**First renewal**

- CTD Module 2 + CTD Module 3 for (for veterinary medicinal products the application may be filed in the NTA format)
- Complete file according to Appendix 3 of the renewal guideline².
- A statement from the Appointed Pharmacist that the complete file according to the requirements of the renewal guideline² is submitted.

**Second or later renewal**

- The documents listed in section 5.5.3.2.2 of the renewal guideline²:
  - Updated and approved specifications for the active ingredient and the final medicinal product.
  - Stability data for the last five years as well as completion of stability data that was submitted incomplete in the past.
  - Complete file (in the case that many significant changes occurred)
- A statement from the Appointed Pharmacist that the complete file according to the requirements of the renewal guideline² is submitted.

**Laboratory file, samples of the medicinal product and standards¹**

- Samples of the final product
  - Instructions for shipping and storage temperatures
- Reference standard (standard) for the active ingredient
Annex XII - Renewal Checklist for Biologicals – Israel

<table>
<thead>
<tr>
<th>The Institute of Standardization and Control of Pharmaceuticals</th>
<th>Guideline for submission of applications for renewal of a quality certificate for a medicinal product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline N° EX-005/02</td>
<td>Page 19 of 19</td>
</tr>
</tbody>
</table>

- [ ] Instructions for shipping and storage temperatures
- [ ] Reference standards for metabolic products
- [ ] Instructions for shipping and storage temperatures
- [ ] Laboratory file according to the Institute Circular dated 4.12.2008

Signature of the Appointed Pharmacist ___________________ Date _______________
Appendix 4:

Checklist for submission of applications to the Biological Products Unit

Renewal

EX-005A/02

CTD Module 1

- Cover letter
- Quality certificate
- Appendix to the Quality certificate
- Original receipt
- Questionnaire (Appendix 6, parts A and B)
- CPP
- Valid GMP approval for all manufacturing sites (active ingredient, final product, solvent, testing and release sites)
- A QP declaration for suppliers of active ingredients¹
- Valid TSE declaration
- Valid CEP approvals for materials from living organisms that are used directly on the manufacturing process
- Analysis certificate for the active ingredient and the final medicinal product
- MSDS
- Physician leaflet
- Response to previous obligations
- List of variations since the most recent renewal
- Variations of type IA at the time of renewal according to the checklist for the application for variations

¹ According to the guideline regarding the QP declaration, EX-014

Ministry of Health - Pharmaceutical Division
The Institute for Standardization and Control of Pharmaceuticals
P.O.B 33410 Jerusalem 91342 Fax: 02-6551777 Tel: 02-6551717
Quality File

- Composition (as stated in the file)
- Flowchart for the manufacturing process of the active ingredient
- Specifications of the active ingredient
- Current stability data for the active ingredient
- Packaging data for the active ingredient
- Flowchart for the manufacturing process of the final medicinal product
- Specifications of the final product
- Current stability data for the final medicinal product
- Packaging data for the final medicinal product
- Risk evaluation regarding Viruses and TSE (vCJD for medicinal plasma and urine products)
- Update of the Active Substance Master File
- Update of the Plasma Master File including approval from the authorities\(^2\)
- Complete manufacturing file, if not submitted during the original registration

Laboratory

- Samples\(^3\)
  - Instructions for shipping and storage
  - Reference standards (type and quantity as agreed upon with the Unit)\(^2\)
    - Instructions for shipping and storage
    - A page with explanations linking the name of the reference standard with the final product.

---

\(^2\) For plasma files or for files containing an ingredient whose origin is in the plasma

\(^3\) According to Guideline No. EX-001.01: "Submission of samples and reference standards when submitting to the Institute", downloadable from [http://www.health.gov.il](http://www.health.gov.il)
The Institute of Standardization and Control of Pharmaceuticals  
Guideline for submission of applications for renewal of a quality certificate for a medicinal product

Guideline No EX-005/02  
Page 16 of 19

Laboratory File
☐ Testing methods in coordination with the unit.
☐ Validation methods in coordination with the unit.
☐ Specifications of the final product
☐ Analysis certificate of the samples and reference standards, in coordination with the Unit.
☐ MSDS

Signature of the Appointed Pharmacist _______________ Date _______________
Annex XIII - Renewal Checklist – Application form for Marketing and Renewal Application - Jordan

**Drug Registration Application Form**

**Registration Department / Drug Directorate**

* Application Purpose (check one) : Registration [ ] Re-Registration [ ]

* Application Type (check one) :
  - New Drug Application (ND) [ ]
  - Generic Drug Application (GD) [ ]
  - Biological Drug Application (BD) [ ] (sera & vaccine).
  - Herbal Drug Application (HD) [ ]

**Notes For Applicants**:
- This application (7 pages).
- All information should be filled & presented in Arabic or English language.
- This form should be filled for every pharmaceutical form / every concentration.

- The manufacturer through the local agent shall forthwith inform Registration department:
  - If any information received by him that casts doubt on the continued validity of the data which was submitted with, or in connection with the application for the product license for the purpose of being taken into account in assessing the safety, quality or efficacy of any drug to which the license relates.
  - If there any change in his name and address or the Marketing Authorization Holder Name & address.
  - If there any change he propose to make concerns the information in this application.
4- Administrative Information :

4.1 DRUG :
4.1.1 Name: ......................................................
4.1.2 Pharmaceutical Form: ................................
4.1.3 Package Size(s) ...........................................
4.1.4 Strength ...................................................
4.1.5 Package Size and Strengths Used in the Country of Origin ........................................

4-2- MANUFACTURERS

4.2.1 - Responsibility of the facility: Bulk Manufacturer:
- Name: ............................................................
- Address: ........................................................

4.2.2 - Responsibility of the facility: Primary Packaging:
- Name: ............................................................
- Address: ........................................................

4.2.3 - Responsibility of the facility: Secondary Packaging:
- Name: ............................................................
- Address: ........................................................

4.2.4 - Responsibility of the facility: Batch Release of finished product:
- Name: ............................................................
- Address: ........................................................

(Note: including manufacturing sites of any diluent/solvent presented in the same pack or in a separate container but forming part of the medicinal product.

4-3- Marketing Authorization Holder Name & Address (branch supplying Jordan with this Drug):

........................................................................................................................................
........................................................................................................................................
........................................................................................................................................
........................................................................................................................................
........................................................................................................................................
4-5 PRICES:

4.5.1 Export Price to Jordan (FOB / C&F): .....................................................

4.5.2 Price to pharmacist in the Country of Origin: ...........................................

4.5.3 Price to public in the Country of Origin: ....................................................

4.5.4 Price to pharmacist relating to Health Insurance in the Country of Origin (if applicable): ....

5. Qualitative & Quantitative Composition:

5.1 Active Pharmaceutical Ingredient's (API):

5.1.1 Name and Quantities: .................................................................................

.................................................................................................................................

NOTE:
1. The name of the active constituent should be:
a) The Approved Name (i.e. the name appearing in the List of Approved Names prepared by the British Pharmacopoeia Commission).
b) Monograph Name (if not an Approved Name, a reference to the compendium in which the monograph appears should be given).
c) U.S. Adopted Name (USAN).
d) International Non-Proprietary Name (INN).
e) Chemical Name and Alternative chemical names.
f) Proprietary or trade name (S). 
g) Other names (if any).
2- Reference should be made to determine what monograph the active ingredient follows.
3- The quantity of the active constituent should be declared per dose, or when this is not practicable, as a percentage of the total formulation.
4- Names and quantities are to be shown on any label, leaflet, or descriptive material.

5.1.2 Source/s of (API):

(Maximum Three Manufacturer Acceptable) Refer to the Raw Material Criteria decision No (15) date 9/5/2007:

<table>
<thead>
<tr>
<th>Manufacturer Name of API</th>
<th>Country</th>
<th>Has a Ph.Eur. Certificate of suitability*</th>
<th>Holder Name (of the certificate) &amp; Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: Provide last updated copy of the Certificate of suitability (CoS) in the technical file.
*If CoS is not available a certified copy of GMP certificate for API manufacturer should be included in the file.
5.2 **In Active Ingredients (Excipients):**

<table>
<thead>
<tr>
<th>Name of ingredient</th>
<th>Unit amount per dose</th>
<th>Unit amount (mg/g)</th>
<th>Action</th>
<th>Source (Chemical, Human, Animal, Plant)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.3 **Coloring Flavoring and Perfume Compounds:**

........................................................................................................................................

5.4 **Overage:**

........................................................................................................................................

*(Note: If an overage is included in the formulation for any constituent, it should be stated in what percentage and for what reason).*

---

6. **Containers, Closure and Administrative Device:**

6.1 **Container used for the product/package (description of material):**

6.1.1 Primary package material: .................................................................

6.1.2 Secondary package material: .............................................................

6.2. **Proposed Storage Conditions:** ...........................................................

6.3. **Proposed Storage conditions after first opening/or after reconstitution or dilution:**

..............................................................................................

6.4. **Proposed Shelf Life of the product:** ..................................................

6.5. **Proposed shelf life after first opening/or (after reconstitution or dilution):**

..............................................................................................

6.6. **For Generic drugs: specify the Shelf life & Storage Conditions for the Reference Drug/Originator drug:** ........................................
7. Clinical Use:

7.1 Summary of Product Characteristics (SmPC) (Revision Date: .............)

7.1.1. Recommended Clinical Use:

7.1.2. Proposed Route(s) of Administration:

7.1.3. Recommended Dosage:

7.1.4. For Adults:

7.1.5. For Children and Infants by age groups (if appropriate):

7.1.6. Pharmacotherapeutical group (ATC Code):

8. Clinical Trials and Studies:

8.1. Give a Summary of the Trials and Results:

NOTE:

a. Name and type of the Studies done on the product (Clinical Studies, Bioequivalence, Bioavailability, ......)
b. Number of patients on test medication on completion of trials.
c. Dosage employed in trials expressed as a mean and as a range.
d. Results achieved from study’s Conclusions and comments.

8.2. If Generic Drug Specify the Name of the Reference drug:
9. Label and Inserts :

9.1. Type of the package leaflets to be inserted in the package:

- Professional package leaflet ☐  - Patient package leaflet ☐  - Both ☐

Other specify (ex: Instructions leaflet) ☐

(Note: (a) State the revision date of each leaflet.)
Maintenance of Marketing Authorizations in the MENA Region

Annex XIV – Application Form for Renewal - Palestine

Registration Renewal Application Form

To: The Director of Drug Registration Department

We hereby request that the registration of the following medicinal product to be renewed.

- Applicant information:
  - Applicants Name (Responsible pharmacist): .................................................................
  - Manufacturer name and address: ...................................................................................
  - Name and address of the importer (for imported drugs only): ...........................................

- Product information:
  - Registration No.: ...........................................................................................................
  - Name of the medicinal product: ......................................................................................
  - Dosage form and strength: ..............................................................................................
  - Quantity per pack: ...........................................................................................................
  - Purpose of re-registration:
    - ( ) Manufacturing and marketing.
    - ( ) Import and marketing.
    - ( ) Amended/approved restrictions on the marketing of the product:

Signature of the responsible pharmacist/Vet. Date

-----------------------------------------------

Attachments:
- ☐ Original receipt confirming payment of re-registration fees.
- ☐ Latest master formula.
- ☐ Latest method(s) of analysis for the finished products.
- ☐ Shelf-life stability study.
- ☐ Latest packaging materials specifications (primary and secondary) attached with samples from secondary packaging materials or artwork.
- ☐ Valid certificate of pharmaceutical product (CPP) original legalised (Imported drugs).
- ☐ Sufficient samples from finished products and reference materials for analysis purposes.

For Office use only:
- Name of receiver: ..........................................................
- Date receiving: ..........................................................
- Remarks: ........................................................................

Signature: ............................................................ Date: .............................................
Annex XV – DMP Application Form for Renewal - Morocco

<table>
<thead>
<tr>
<th>Nom et dosage</th>
<th>Formes et présentation</th>
<th>Etablissement pharmaceutique industriel</th>
<th>Type de produit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Produit sous licence:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oui</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Autre</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type de modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: Réactualisation-quinquennale</td>
</tr>
<tr>
<td>B: Transfert de titularité (changement du titulaire d'AMM au Maroc)</td>
</tr>
<tr>
<td>C: Changement de la mise sur le marché des médicaments</td>
</tr>
<tr>
<td>D: Modification des indications thérapeutiques</td>
</tr>
<tr>
<td>E: Modification du conditionnement secondaire</td>
</tr>
<tr>
<td>F: Mise à jour des mentions légales</td>
</tr>
<tr>
<td>G: Cession de dossier</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Partie réservée à l'administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lettre de demande en 5 exemplaires</td>
</tr>
<tr>
<td>Copie du récépissé du droit fixe d'enregistrement</td>
</tr>
<tr>
<td>AMM du pays d'origine en vigueur (produit sous licence)</td>
</tr>
<tr>
<td>Certificat du Produit Pharmaceutique dans le cas où la mise sur le marché dans le pays d'origine ne prévoit pas la réactualisation de l'AMM (produit sous licence)</td>
</tr>
<tr>
<td>Résultat des caractéristiques du produit du pays d'origine réactualisé</td>
</tr>
<tr>
<td>Traduction officielle de l'AMM du pays d'origine en langue française et tout autre document rédigé dans une langue autre que le français ou l'arabe</td>
</tr>
<tr>
<td>Pèche signalétique mise à jour</td>
</tr>
<tr>
<td>Copie d'AMM marocaine en vigueur</td>
</tr>
<tr>
<td>La notice et l'étiquetage modifié en français et en arabe</td>
</tr>
<tr>
<td>Dossier clinique (sur CD) et rapport d'expert (sur papier)</td>
</tr>
<tr>
<td>Accord de transfert de titularité délivré par le Ministère de la santé</td>
</tr>
<tr>
<td>Projet du nouveau conditionnement secondaire</td>
</tr>
<tr>
<td>Accord de dépôt du dossier technique au niveau LNCM</td>
</tr>
<tr>
<td>Copie du dossier de change de statut délivré par le Ministère de la santé</td>
</tr>
<tr>
<td>Lettre de cession du dossier du titulaire de l'AMM dans le pays d'origine à l'EPF Marocain</td>
</tr>
</tbody>
</table>

1. Si le changement de nom n'a pas eu lieu dans le pays d'origine, l'accord du titulaire d'AMM à l'étranger est à déposer.
2. A déposer l'aide et le nouveau modèle de la notice avec tableau comparatif.
3. À déposer l'aide et le nouveau modèle de l'étiquetage.
4. Revue de la bibliographie clinique en cas de générique.
5. Dans le cas de changement de statut de la fabrication locale à l'importation.
6. Seulement lorsque la durée de validité restante de l'AMM est ≥ 9 mois.
7. Copie du dossier de paiement déjà octroyé pour le transfert de titularité.

**ÉTABLISSEMENT PHARMACEUTIQUE INDUSTRIEL**
Pharmacie responsable ou son représentant:
Date: Signature et cachet:

**DIVISION DE LA PHARMACIE**
Service d'enregistrement des médicaments et des produits de santé:
Dossier recevable: Dossier irrecevable:
Date: Signature:
## Maintenance of Marketing Authorizations in the MENA Region

### Annex XVI – LCNM Application Form for Renewal - Morocco

<table>
<thead>
<tr>
<th>Nom du produit Forme/Dosage/Présentation:</th>
<th>DCI:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cochez les cases correspondantes</td>
<td></td>
</tr>
<tr>
<td>□ Principe</td>
<td>□ Générique</td>
</tr>
</tbody>
</table>

### Type de produit:
- □ Chimique
- □ Radio pharmaceutique
- □ Biologique
- □ Homéopathique
- □ Vaccin
- □ Autre

### Type de dossier:
- □ Renouvellement quinquennal : circulaire 48
  - circulaire 49
- □ Transfert de titularité : avec changement de site de fabrication de PF
  - sans changement de site de fabrication de PF
- □ Modification pharmaceutique de Type I
- □ Modification pharmaceutique de Type II (avec rapport d’expert)
- □ Compléments de Stabilité
- □ Variation sujet de la Note d’information

### Documents/Pièces à fournir:

**Pour une demande de RO d’une spécialité pharmaceutique dont l’AMM à enregistrement est octroyée selon la circulaire 49:**
- □ Lettre de demande (explicite) avec cachet de la division de la pharmacie.
- □ AMM Maroc en vigueur
- □ Fiche signalétique
- □ Formulaire joint dûment rempli.
- □ Extraits de la DCP concernant les éléments suivants (copie de la documentation déjà déclarée au LCNM signé par le pharmacien responsable):
  - La composition unitaire.
  - Le conditionnement primaire.
  - La conclusion sur la stabilité du produit fini.
  - Les sites de fabrication du produit fini et de (s) PA (s), es précisant les noms et les adresses.
  - La (s) lettre (s) d’engagement du (s) fabricant(s) du PA
- □ Attestation sur l’honneur que le produit n’a subi aucune variation non déclarée durant sa dernière période quinquennale.
Maintenance of Marketing Authorizations in the MENA Region
Enregistrement

Formulaire de dépôt d’un dossier technique pour le renouvellement quinquennal et/ou de mise à jour d’une spécialité pharmaceutique à usage humain

Direction des Médicaments et de la Pharmacie

- Déclaration type* (voir ci-dessous), signée par le pharmaciens responsable
- Rapport d’expert pour toute variation de type II
- Accord de l’autorisation de réglementation du pays d’origine sur les variations pour les produits à l’importation et sous licence.
- Documentation chimique biologique et pharmaceutique à fournir pour le type de la modification proposée.
- Liste chronologique de toutes les modifications en attente d’autorisation avec date de dépôt de tout type de variation
- Présenter séparément de la documentation chimique et pharmaceutique les copies signées par le pharmacien responsable des pièces suivantes dans les cas où la variation touche l’AMM.
  - La composition unitaire de la spécialité pharmaceutique et/ou.
  - La description du conditionnement primaire du produit fini et/ou.
  - Les sites de fabrication, de conditionnement primaire et de contrôle du produit fini et/ou.
  - La conclusion sur la durée de validité et les conditions de conservation du produit fini.

- Complément de stabilité:
- Copie du courrier du LNCM demandant les Etudes de Stabilité
- Les nouvelles données de stabilité
- Copie de l’engagement
- Courrier du laboratoire pharmaceutique
  (tout engagement de stabilité doit comporter l’échéancier, la date de fabrication, les numéros des lots le type de conditionnement primaire, la taille du lot et la date de remise des données au LNCM).

*: Présenter les déclarations et annexations suivantes (séparément de ce formulaire).
- Aucune modification n’a été faite sur ce produit en dehors de celle(s) indiquée(s) dans cette demande;
- La documentation fournie ne présente aucune autre modification que celles décrites dans cette demande (sauf pour les demandes de modifications déposées en parallèle);
- Les changements demandés n’affectent pas la qualité, l’efficacité ou l’innocuité du présent médicament;
- La documentation transmise correspond à celle exigée pour une modification de Type IA ou IB;
- Les conditions prévues pour cette modification sont remplies.
- Autres:

NB : les compléments aux courriers du LNCM doivent être accompagnés des éléments suivants :
- le complément demandé par le LNCM
  - Complément de la documentation
  - Copie du courrier de demande de complément
  - Courrier de réponse du laboratoire pharmaceutique

<table>
<thead>
<tr>
<th>LNCM:</th>
<th>LABORATOIRE PHARMACEUTIQUE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date de réception:</td>
<td>Signature du responsable affaire réglementaire:</td>
</tr>
<tr>
<td>Accusé de réception:</td>
<td></td>
</tr>
</tbody>
</table>

143
Annex XVII – Application Form for Renewal - Algeria
Maintenance of Marketing Authorizations in the MENA Region

Homologation dans d’autre pays :

Conditionnement :

Classification (vital, essentiel, non essentiel) :

Je soussigné(e)…………………………………demandeur ou représentant déclare que toute les informations données dans cette demande et ses annexe sont exactes.

Signature du demandeur
ou du représentant

Date :

N.B : le présent document doit être authentifié par les services consulaires de l'Ambassade d'Algérie.

ANNEXE I

STATUT ADMINISTRATIF DU PRODUIT :

ASPECT ET COMPOSITION DU PRODUIT :

Nom du produit :

Nom du demandeur :

Forme pharmaceutique et aspect (Taille, couleur etc …)

Autorisation de mise sur le marché du pays d’origine (Copie du certificat d’autorisation de mise sur le marché des autorités compétentes datant au moins d’une année par rapport à la date du dépôt du dossier de demande d’enregistrement

-Nombre d’exemplaires des étiquettes : 10
-Nombre d’exemplaires de notice du produit : 10
-Nombre d’exemplaires d’emballage du produit : 10

Autorisation de mise sur le marché dans d’autres pays (Copie du certificat d’autorisation de mise sur le marché des autorités compétentes datant de moins d’une année par rapport à la date du dépôt du dossier de demande de demande d’enregistrement.

-Nombre d’exemplaires des étiquettes : 10
-Nombre d’exemplaires de notice du produit : 10
-Nombre d’exemplaires d’emballage du produit : 10
Pour chaque pays dans lequel le produit est fabriqué, joindre un certificat délivré par l’autorité compétente au maximum un an avant la date de la présente demande conformément au système organisation mondiale de la santé de certification de la qualité des produits pharmaceutiques entrant dans le commerce international.

**ECHANTILLONS** :

Joindre 10 échantillons dans l’emballage proposé à la commercialisation pour chaque forme et dosage.

**Texte des notices d'utilisation du produit selon les rubriques suivantes** :

Composition du produit

Indications

Posologie et administration

Contre indication

Réaction indésirables

Précaution et allaitement

Traitement des surdosages

Interactions avec d’autres médicaments ou avec des aliments

Conditions de conservations.
### ANNEXE II

**ASPECT ET COMPOSITION DU PRODUIT :**

<table>
<thead>
<tr>
<th>Nom du produit:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nom du demandeur:</td>
<td></td>
</tr>
<tr>
<td>Forme pharmaceutique et aspect (taille, couleur etc...):</td>
<td></td>
</tr>
</tbody>
</table>

#### a) Principes actifs (D.C.I, OMS ou autres pharmacopées):**

<table>
<thead>
<tr>
<th>Formulaire du principe actif:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantité et dose centésimale du principe actif contenues dans une dose unitaire (ml liquide).</td>
<td></td>
</tr>
</tbody>
</table>

#### b) Excipient:

<table>
<thead>
<tr>
<th>Quantité et dose centésimale et raison d’inclusion</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nature de l’excipient:</td>
<td></td>
</tr>
<tr>
<td>- Colorant</td>
<td></td>
</tr>
<tr>
<td>- Conservateur</td>
<td></td>
</tr>
<tr>
<td>- Antioxydant</td>
<td></td>
</tr>
<tr>
<td>- Stabilisant</td>
<td></td>
</tr>
<tr>
<td>- Aromatisant</td>
<td></td>
</tr>
<tr>
<td>- Gaz propulsor (aérosol)</td>
<td></td>
</tr>
</tbody>
</table>

Spécification des matériaux de conditionnement en contact direct avec le médicament.

ANNEXE III
PROCEDURE DE FABRICATION ET DE CONTROLE

Nom du produit:

Nom du demandeur:

Forme pharmaceutique et son aspect (taille, couleur etc…).

Joindre une description du processus de développement de la formule avec justification du choix et du dosage des excipients.

L’étude de la biéquivalence de ce produit lorsqu’elle a été effectuée. Si oui donner des détails, Si non, indiquer pourquoi.

Pour les médicaments dits génériques à index thérapeutiques faible l’étude de la bioéquivalence relative est exigée.

Joindre un résumé de fabrication

Joindre une description des procédés de contrôle appliqués aux matières premières y compris les testes, micro biologiques toxico logiques le cas échéant.

Joindre une description des contrôles et des essais effectués au cours du processus de fabrication.

Décrire les essais et dosage effectuées sur le produit final.

Donner l’intégralité des spécifications relatives au produit final.

Durée de conservation proposée

Fournir des données justifiant l’estimation de la durée de conservation.
Annex XX – Required documents for renewal of CP products

Annex 2

Documents to submit

Renewal applications should be submitted in eCTD format and have to contain the documents listed below.

Module 1:

1.0 Cover letter

1.2 Renewal Application form with the following annexes:

- List of all authorised product presentations for which renewal is sought in tabular format (following the template for Annex A to CHMP Opinion)

- Details of contact persons:
  - Qualified person in the EEA for pharmacovigilance
  - Contact person in the EEA with the overall responsibility for product defects and recalls
  - Contact person for scientific service in the EEA in charge of information about the medicinal product

- List of EU Member states/Norway/Iceland where the product is on the market and indicating for each country which presentations are marketed and the launch date

- Chronological list of all post-authorisation submissions since the grant of the Marketing Authorisation or last renewal: a list of all approved or pending Type IA/IB and Type II variations, Extensions, Art 61(3) Notifications, USR, and PSURs, giving the procedure number (where applicable), date of submission, date of approval (if approved) and brief description of the change.

- Chronological list of conditions and Specific Obligations submitted since the granting of marketing authorisation or the last renewal indicating scope, status, date of submission and date when the condition/obligation was fulfilled (where applicable)

- Revised list of all remaining conditions and Specific Obligations (where applicable)

- A statement, or when available, a certificate of GMP compliance, not more than three years old, for the manufacturer(s) of the medicinal product listed in the application issued by an EEA competent authority or MRA partner authority. A reference to the Community EudraGMP database, if available will suffice.

- For manufacturing sites of the medicinal product not located in the EEA or in the territory of an MRA partner, a list of the most recent GMP inspections carried out indicating the date, inspection team and outcome.

- In accordance with Article 46(f) of Directive 2001/83/EC manufacturing authorisation holders are required to use as starting materials only active substances which have been manufactured in accordance with the detailed guidelines on good manufacturing
practice for starting materials as adopted by the Community. The following declarations are required:

- A declaration by the Qualified Person (QP) of each of the manufacturing authorisation holders (i.e., located in the EEA) listed in the application form where the active substance is used as a starting material.

- A declaration by the Qualified Person (QP) of the manufacturing authorisation holder(s) listed in the application as responsible for batch release.

These declarations should state that all the active substance manufacturer(s) referred to in the application form operate in compliance with the detailed guidelines on good manufacturing practice for starting materials.

1.3.1 Summary of Product Characteristics, Labelling and Package Leaflet:
A clean version of the SmPC, Annex II, outer and inner labelling and Package Leaflet in English has to be provided. In addition, a word version highlighting potential changes proposed by the MAH should also be included in the application.

1.3.3 Specimens:
At renewal, EMA will perform a new check of the specimens across all marketed product presentations.

Relevant example specimens should be provided to the EMA as part of the renewal application, for each strength, pharmaceutical form, and container type in the smallest marketed pack-size.

Ideally, multi-lingual specimens should be provided, but if not available, a single-language specimen may be submitted.

As such, the EMA will receive and check at least one example specimen of the whole range of marketed product presentations after 5 years, in one submission.

In case the MAH plans to change the overall design and readability of the labelling and/or package leaflet around the time of renewal, submission of specimens of the “old” product design will not be necessary. In case the MAH wishes to receive EMA feedback on their proposed new packaging in advance of the specimen submission and review, this approach should however be discussed with the EPL/PM in advance of the renewal submission.

1.4 Information about the Expert:
In cases where MAHs wish to distinguish these declarations from any previous declarations, the EMA Renewal procedure Number may be included on top.

1.4.1 Information about the Expert: Quality (incl. Signature + CV)
1.4.2 Information about the Expert: Non-clinical (incl. Signature + CV) - if applicable
1.4.3 Information about the Expert: Clinical (incl. Signature + CV)

1.8.2 Risk Management Plan:
The updated RMP and where relevant, the new RMP.

Where there are no new data justifying changes to the latest approved RMP, the MAH should provide in the clinical overview declaration and confirm that the current approved RMP remain unchanged and applicable.
Where there is no RMP for the medicinal product, this should be stated in the cover letter.

Module 2:

2.3 Addendum to Quality Overall Summary:

The Addendum should include a declaration of compliance with Article 16(1) of Regulation (EC) No 726/2004, which obliges the MAH “to take account of technical and scientific progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods”.

The Addendum to the Quality Overall Summary should also include:

- Confirmation that all changes relating to the quality of the product have been made following applications for variations and that the product conforms to current CHMP Quality guidelines.
- Currently authorised specifications for the active substance and the finished product (with date of latest approval and procedure number)
- Qualitative and quantitative composition in terms of the active substance(s) and the excipient(s) (with date of latest approval and procedure number)

2.4 Addendum to Non-clinical Overview:

An Addendum to the non-clinical Overview is not systematically required as part of the renewal application.

When new data are submitted in the non-clinical Addendum, a critical discussion must be submitted as part of the renewal application, supporting the benefit-risk balance re-evaluation for the product taking into account any new non-clinical data accumulated since the initial MAA or the last renewal, or any relevant new information in the public domain.

In the case where no new non-clinical data have been gathered since the granting of the MA or the last renewal, this may be stated in the Addendum to the Clinical Overview.

2.5 Addendum to Clinical Overview:

A critical discussion should be provided within the Addendum to the Clinical Overview. It should address the current benefit-risk balance for the product on the basis of the PSUR data and safety/efficacy data accumulated since the granting of the MA or the last renewal, making reference to relevant new information in the public domain. The discussion should clearly reflect the data previously included in the PSUR and the new data that have been collected since the DLP of the last PSUR up to the DLP of the renewal that should not exceed 90 days prior to the renewal submission.

The Addendum to the Clinical Overview should contain the following information**:

- History of pharmacovigilance system inspections (date, inspecting authority, site inspected, type of inspection and if the inspection is product specific, the list of products concerned) and an analysis of the impact of the findings overall on the benefit-risk balance of the medicinal product.
- Worldwide marketing authorisation status: overview of number of countries where the product has been authorised and marketed worldwide.
• Actions taken for safety reasons during the period covered since the initial marketing authorisation or since the last renewal until to the DLP of the renewal: description of all significant actions related to safety that had a potential influence on the benefit-risk balance of the authorised medicinal product (e.g. suspension, withdrawal, temporary halt or premature ending of clinical trial for safety reasons, issue requiring communication to healthcare professionals...). Among these, actions taken from the DLP of the last PSUR up to the DLP of the renewal should be clearly highlighted.

• Significant changes made to the Reference Information (RI) during the period covered since the initial marketing authorisation or since the last renewal. In this section, the new changes made from the DLP of the last PSUR up to the DLP of the renewal should be clearly highlighted.

• Estimated exposure and used patterns: data on cumulative exposure of subjects in clinical trials as well as of patients from worldwide post-marketing exposure per EU and non EU regions. If the marketing authorisation holder becomes aware of a pattern of use of the medicinal product considered relevant for the interpretation of the safety data, a brief description should be provided; such patterns may include in particular off-label use.

• Data in summary tabulations: Summary tabulations of serious adverse events from clinical trials as well as summary tabulations of adverse reactions from post-marketing data sources reported during the period covered since the initial marketing authorisation or since the DLP of the last renewal up to the DLP of the renewal.

• Summaries of significant safety and efficacy findings from clinical trials and non-interventional studies during the period covered by the renewal. It should also address whether milestones from post-authorisation safety studies, post-authorisation efficacy studies, studies included in the pharmacovigilance plan of the RMP and studies conducted as condition or specific obligations of the marketing authorisation have been reached in accordance with agreed timeframes. New data since the DLP of the last PSUR up to the DLP of the renewal should be clearly highlighted.

• Overview of signals: High level overview of signals for which evaluation was completed during the period covered by the renewal and any action taken or planned; and high level overview of ongoing signals (i.e. that are undergoing evaluation at the DLP of the renewal application) should be provided. The information should be provided in a table.

• Signal and risk evaluation: the MAH should summarise signals for which evaluation was completed during the reporting period of the renewal. For signals that became important identified or potential risks or are related to a known risk, a characterisation of the risk should be provided. Evaluation of signals completed from the DLP of the last PSUR to the DLP of the renewal should be clearly highlighted. The MAH should discuss whether any changes are considered necessary in the existing safety concerns and whether any additional risk minimisation activities for the product are warranted, considering the data collected during the period covered by the renewal.

• Relevant information on patterns of medication errors and potential medication errors (even when not associated with adverse outcomes) during the period covered by the renewal. Such information may be relevant to the interpretation of safety data or the overall benefit-risk balance evaluation.
• Literature: review of important literature references published during the period covered since the initial marketing authorisation or since the DLP of the last renewal that had a potential impact on the benefit-risk balance of the medicinal product.

• Benefit evaluation: the MAH should summarise important efficacy and effectiveness information (including information on lack of efficacy) for the period covered since the initial marketing authorisation or since the DLP of the last renewal until the DLP of the renewal.

• Benefit-risk balance: a discussion on the benefit-risk balance for the approved indication should be presented, based on the above information.

• Late-breaking Information: The MAH should summarise the potentially important safety, efficacy and effectiveness findings that arise after the DLP of the renewal but during the period of preparation of the addendum to the clinical overview.

**Marketing authorisation holders are advised to consider the Good Vigilance Practice Module VII on PSUR as guidance for the preparation of the above sections of the clinical overview.

The Clinical Expert Statement should:

• Confirm that no new clinical data are available which change or result in a new benefit-risk balance evaluation.

• Confirm that the product can be safely renewed at the end of a 5-year period for an unlimited period, or any action recommended or initiated should be specified and justified.

• Confirm that the authorities have been kept informed of any additional data significant for the assessment of the benefit-risk balance of the product concerned.

• Confirm that the product information is up to date with the current scientific knowledge including the conclusions of the assessments and the recommendations made publicly available on the European medicines web-portal.
Annex XXI – Required documents for renewal of DCP or MRP products

ANNEX 3 - Documents to submit

Renewal applications with full documentation have to contain a consolidated version of the file, containing at least the documents listed below. Further documentation should be available from the MAH on request if considered necessary to complete the benefit/risk assessment.

In certain cases (see section 3.6 and also 3.5 above), certain elements of the clinical overview addendum can be omitted.

In certain cases, (i.e. in the specific cases when a shortened renewal procedure can be followed, see sections 3.3, 3.4, 3.5, 3.8 and 3.14 above) the consolidated file may be reduced to a cover letter from the MAH accompanied by an application form (without annexes) and a declaration that full documentation will be available for submission on request of a CMS. The cover letter should include confirmation that no new data are available that changes, or would result in a re-evaluation of, the benefit/risk balance and that the product information is up to date with current scientific knowledge (or otherwise a commitment to update the product information by the appropriate variation within 3-months of the finalisation of the renewal). In cases where a shortened renewal procedure concerns a MA following an informed consent/duplicate, the MAH should also confirm in the cover letter that the dossier of the ‘mother licence’ and the dossier of the informed consent/duplicate are still identical.

The consolidated file should be presented as follows in accordance with the appropriate headings and numbering of the EU-CTD format:

Module 1:
1.0 Cover letter
1.1 Comprehensive table of contents
1.2 Renewal Application form with the following annexes:
   - List of all authorised product presentations for which renewal is sought, in tabular format;
   - Details of contact persons:
     - Qualified person in the EEA for pharmacovigilance;
     - Contact person in the EEA with the overall responsibility for product defects and recalls
     - Contact person for scientific service in the EEA in charge of information about the medicinal product;
   - List of EU Member States/Norway/Iceland where the product is on the market and indicating for each country which presentations are marketed and the launch date;
   - Chronological list of all post-authorisation submissions since grant of the MA or last renewal: a list of all approved or pending Type IA & Type IAmo, Type IB and Type II variations, Extensions, Art 61(3) Notifications, and PSURs giving the procedure number (where applicable), date of submission, date of approval (if approved) and brief description of the change;
   - Chronological list of conditions/post-authorisation commitments submitted since the granting of the MA or the last renewal indicating scope, status, date of submission and date when issue resolved (where applicable);
   - A revised list of all remaining conditions (where applicable);
   - A statement, or when available, a certificate of GMP compliance, not more than three
Module 1:

years old, for the manufacturer(s) of the medicinal product listed in the application issued by an EEA competent authority or MRA partner authority. A reference to the Community EudraGMP database, if available, will suffice.

- For manufacturing sites of the medicinal product not located in the EEA or in the territory of an MRA partner, a list of the most recent GMP inspections carried out indicating the date, inspection team and outcome.

- In accordance with Article 46(f) of Directive 2001/83/EC manufacturing authorisation holders (i.e. located in the EEA) are required to use as starting materials only active substances which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials as adopted by the Union. The following declarations are required:
  - A declaration by the Qualified Person (QP) of each of the manufacturing authorisation holders listed in the application form where the active substance is used as a starting material.
  - A declaration by the Qualified Person (QP) of the manufacturing authorisation holder(s) listed in the application as responsible for batch release.

These declarations should state that all the active substance manufacturer(s) referred to in the application form operate in compliance with the detailed guidelines on good manufacturing practice for starting materials.

1.3 Summary of Product Characteristics, Labelling and Package Leaflet

A relevant example of the proposed texts for SmPC, outer and inner labelling and Package Leaflet in English must be provided with any proposed changes (highlighted).

1.4 Information about the Experts.

In cases where MAHs wish to distinguish these declarations from any previous declarations, the renewal procedure number may be included on top.

1.4.1 Information about the Expert – Quality (incl. Signature + CV).

1.4.2 Information about the Expert – Non-Clinical (incl. signature + CV) – if applicable.

1.4.3 Information about the Expert – Clinical (incl. Signature + CV).

1.8.2 Risk Management Plan (if applicable).

The updated RMP, if necessary. Where there are no new data justifying changes to the latest approved RMP, the MAH should provide such a declaration and confirm that the current approved RMP remains unchanged and applicable.

If there is not an RMP for the product and this is not required, this should be stated in this section.

Module 2:

2.3 Addendum to the Quality Overall Summary

The Quality Expert should include a declaration of compliance with Directive 2001/83/EC which obliges the MAH to take account of technical and scientific progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods.

The Addendum to the Quality Overall Summary should also include:

---

2 According to Article 46a (1) of Directive 2001/83 and Article 50a (1) of Directive 2001/83, manufacture includes complete or partial manufacture, import, dividing up, packaging or presentation prior to its incorporation into a medicinal product, including re-packaging or re-labelling as carried out by a distributor.

3 Starting materials manufactured from blood or blood components are excluded from this requirement.
Module 2:

- Confirmation that all changes relating to the quality of the product have been made following applications for variations and that the product conforms to current CHMP Quality guidelines;
- Confirmation of currently authorised specifications for the active substance and the finished product (with date of latest approval and procedure number);
- Qualitative and quantitative composition in terms of the active substance(s) and the excipient(s) (with date of latest approval and procedure number);

2.4 Addendum to the Non-Clinical Overview

An Addendum to the Non-Clinical Overview is not systematically required as part of the renewal application.

If no new non-clinical data have been gathered, this will be reflected in the addendum to the clinical overview.

If an addendum to the non-clinical overview is provided this should include a critical discussion supporting the benefit/risk re-evaluation of the product taking into account any new non-clinical data accumulated since the initial MAA, or the last renewal, or any relevant new information in the public domain.

2.5 Addendum to the Clinical Overview

A critical discussion should be provided within the Addendum to the Clinical Overview addressing the current benefit/risk for the product based on the PSUR data and safety/efficacy data accumulated since the granting of the MA (or the last renewal if applicable), referring to relevant new information in the public domain.

The addendum to the Clinical Overview should contain the following information*:

- History of pharmacovigilance system inspections (date, inspecting authority, site inspected, type of inspection and if the inspection is product specific, the list of products concerned) and an analysis of the impact of the findings overall on the benefit/risk balance of the medicinal product.
- Worldwide marketing approval status: overview of number of countries where the product has been approved and marketed worldwide.
- Actions taken for safety reasons during the period covered since the initial marketing authorisation or since the last renewal (up to 90 days prior to renewal submission): description of significant actions related to safety that had a potential influence on the benefit/risk balance of the approved medicinal product (e.g. suspension, withdrawal, temporary halt or premature ending of clinical trial for safety reasons, issue requiring communication to healthcare professionals...).
- Significant changes to the SmPC (e.g. safety warnings, contraindication, restriction of indication...) during the period covered since the initial marketing authorisation or since the last renewal (up to 90 days prior to renewal submission), or has made changes to the reference safety information that has not yet been agreed for the registered SmPC. Meaningful differences between the reference safety information and the proposals for SmPC should be stated. A proposed SmPC, Package Leaflet and labelling should also be provided.
- Estimated exposure: data on cumulative exposure of subjects in clinical trials as well as of patients from marketing exposure. If the marketing authorisation holder becomes aware of a pattern of use of the medicinal product considered relevant for the implementation of safety data, a brief description should be provided; such patterns may include in particular, off-label use.
Module 2:

- Data in summary tabulations: summary tabulations of serious adverse events from clinical trials as well as summary tabulations of adverse reactions from post-marketing data sources reported during the period covered since the initial marketing authorisation or since the last renewal (until 90 days prior to the renewal submission).

- Summaries of significant safety and efficacy findings from clinical trials and non-interventional studies: description of any significant safety findings that had an impact on the conduct of clinical trials or non-interventional studies. It should also address whether milestones from post-authorisation safety studies, post-authorisation efficacy studies, studies from the RMP pharmacovigilance plan and studies conducted as conditions and obligations of the marketing authorisation, have been reached in accordance with agreed timeframes.

- Literature: review of important literature references published during the period covered since the initial marketing authorisation or since the last renewal (up to 90 days prior to the renewal submission) that had a potential impact on the benefit/risk of the medicinal product.

- Risk evaluation: the MAH should summarise any information related to important safety issues, evaluation and characterisation of risks as well as effectiveness of risk minimisation measures for the period covered since the initial marketing authorisation or since the last renewal (up to 90 days prior to the renewal submission).

- Benefit evaluation: the MAH should summarise important efficacy and effectiveness information (including information on lack of efficacy) for the period covered since the initial marketing authorisation or since the last renewal (up to 90 days prior to the renewal submission).

- Benefit/risk balance: a discussion on the benefit/risk balance for the approved indication should be presented, based on the above information.

- Late breaking information: the MAH should summarise the potentially important safety, efficacy and effectiveness findings that arise after the data lock point but during the period of preparation of the addendum to the clinical overview.

* Marketing authorisation holders are advised to consider the GVP Module VII on PSURs as guidance for the preparation of the above sections of the clinical overview.

The above sections can be omitted from the clinical overview for products authorised under Article 10a and those registered under Article 16a and mutually recognised, unless there is an obligation to submit PSURs for the product as laid down in a condition to the Marketing Authorisation or it is indicated in the list of European Union Reference Dates (EURD) that PSURs are required for products authorised or registered under these articles and containing the substance or combination of substances concerned.

In any event a clinical expert statement will be required and the Clinical Expert should:

- Confirm that no new clinical (or pre-clinical data in the absence of a non-clinical overview) are available which changes or results in a new benefit/risk evaluation. Where there are new pre-clinical data, the MAH should submit a non-clinical expert report as appropriate.

- Confirm that the product can be safely renewed at the end of a 5-year period for an unlimited period, or any action recommended or initiated should be specified and
Module 2:

- Justified.
- Confirm that the authorities have been kept informed of any additional data significant for the assessment of the benefit/risk balance of the product concerned.
- Confirm that the product information is up to date with current scientific knowledge including the conclusions of assessments and recommendations made publicly available on the European medicines web-portal.
Hiermit erkläre ich an Eides statt, die Arbeit selbständig verfasst und keine anderen als die angegebenen Hilfsmittel verwendet zu haben.

Ort, Datum

Unterschrift